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ABSTRACT 
Carbohydrate-based vaccines induce an immune response against surface glycans found on pathogenic 
bacteria and are used to protect children from meningitis and other bacterial diseases. The definition of the 
epitope targeted by protective antibodies is a crucial information for the design, description and even 
registration of glycoconjugate vaccines. 
The aim of this project is the characterization at atomic level of the interaction between Group B 
Streptococcus (GBS) oligosaccharides with functional antibodies mediating bacterial phagocytic killing. 
The specificity of anti-GBS type III polysaccharide (GBS PSIII) antibodies has been ascribed to a 
conformational epitope with an extended helical structure which would be formed by multiple repeating 
units. 
Here fragments of GBS PSIII were obtained by chemical synthesis and by sizing of the native 
polysaccharide from bacterial source. The oligosaccharides (OSs) were purified by ion exchange 
chromatography and were characterized by mass spectrometry, HPLC and NMR analysis.   
First, the obtained OSs were used to characterize the interaction to protective anti PSIII rabbit monoclonal 
antibody (mAb) by competitive ELISA and surface plasmon resonance analysis. The dependence of binding 
affinity on oligosaccharide length was confirmed and the minimal structures showing comparable binding to 
full-length PS III were identified.  
Next, a combination of saturation transfer difference NMR (STD-NMR) and X-ray crystallography was used 
to map at atomic level the interactions in the rabbit mAb-OS complex. The challenging crystallization of the 
carbohydrate-protein complex was achieved and the molecular bases of the antigen-antibody interaction 
were unveiled. 
The obtained results were used to optimize a vaccine based on short GBS PSIII fragments. 
 
 
 
RIASSUNTO 
I vaccini basati su carboidrati inducono una risposta immunitaria contro i glicani della superficie di patogeni 
e sono usati per proteggere i bambini da meningite e altre malattie batteriche. La definizione dell’epitopo 
riconosciuto da anticorpi protettivi è un’informazione cruciale per il design e la registrazione di questi 
vaccini gliconiugati. 
L’obiettivo di questo progetto è la caratterizzazione a livello atomico dell’interazione tra oligosaccaridi 
derivanti dalla capsula di Group B Streptococcus (GBS) e anticorpi funzionali che quindi inducono la 
fagocitosi del batterio. La specificità degli anticorpi verso il polisaccaride del GBS di serotipo III (GBS 
PSIII) è stata attribuita ad un epitopo conformazionale formato da un’estesa elica che si  forma quando si 
hanno un certo numero di unità saccaridiche che si ripetono nella struttura. 
In questo progetto, i frammenti di GBS PSIII sono stati ottenuti sia per sintesi chimica sia  tramite 
depolimerizzazione del polisaccaride nativo estratto dalla capsula del batterio. Gli oligosaccaridi (OSs) sono 
stati purificati tramite cromatografica a scambio ionico e sono stati caratterizzati tramite spettrometria di 
massa, HPLC e analisi NMR. 
Inizialmente gli OSs ottenuti sono stati utilizzati per caratterizzare l’interazione di un anticorpo monoclonale 
(mAb), prodotto in coniglio, protettivo e specifico per PSIII, attraverso studi di competitive ELISA e SPR. 
In seguito, una combinazione di tecniche diverse, tra cui saturation transfer difference NMR (STD-NMR) e 
cristallografia a raggi X, è stata utilizzata per mappare a livello atomico l’interazione tra il mAb di coniglio 
e un OS selezionato sulla base delle analisi precedenti. La riuscita cristallizzazione del complesso 
carboidrato-proteina ha permesso di rivelare le basi molecolari dell’interazione antigene-anticorpo. 
I risultati ottenuti sono stati quindi utilizzati per ottimizzare un vaccino basato su frammenti corti del GBS 
PSIII. 
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CHAPTER 1: INTRODUCTION 
1.1. General principles of vaccination 
The immune responses of mammals can be divided into innate and adaptive immunity. Innate immunity 
fights intruding pathogens in a fast, yet non-specific way and can be considered a first line of defense. Onset 
of adaptive immunity instead is delayed, but all responses are directed specifically against the respective 
intruder. A multitude of pathogen-specific cells are created by clonal expansion of few, “fitting” pre-cursor 
cells. And, once infection is resolved, some of these cells survive in the body to form immunologic memory 
ready to fight the same pathogen faster and more efficiently, when a second encounter occurs. Vaccination 
takes advantage of this potential of adaptive immunity. The principle of vaccination is that exposure to a 
small sample of a disease-causing microorganism - or to a part or portion of it - teaches the immune system 
to rapidly recognize the menace and to create memory that enables the body to fight the real pathogen 
efficiently during a later encounter. Vaccination basically mimics a natural infection without causing 
disease.  Several are the components of host immune responses that are set in motion following vaccination. 
Important vaccine-induced immune effectors are antibodies produced by B lymphocytes. These antibodies 
are capable to recognize and specifically bind to a toxin or a pathogen (or to a portion representative of it).1 
Antibody binding interferes with pathogen entry into host cells or other important functions. Moreover 
bound antibodies facilitate uptake and elimination of the pathogen by other immune cells. Other important 
immune effectors are cytotoxic CD8+ T lymphocytes (CTL) that may limit the spread of infectious agents 
by recognizing and killing infected cells or by secreting specific antiviral cytokines. The generation and 
maintenance of both B and CD8+ T cell responses is supported by growth factors and signals provided by 
CD4+ T helper (Th) lymphocytes, which are historically subdivided into T helper 1 (Th1), T helper 2 (Th2) 
and T helper 17 (Th17) subtypes. These effector cells are controlled by regulatory T cells (Treg) that are 
involved in maintaining immune tolerance.2 Most of the antigens and vaccines trigger both B and T cell 
responses, and the two responses benefit of their interconnection: CD4+ T cells are required for most 
antibody responses, while antibodies exert significant influences on T cell responses to intracellular 
pathogens.3  
Early protective efficacy of a vaccine is often conferred by microorganism-specific antibodies. But just 
triggering a specific antibody response is not sufficient. The quality of such antibody responses, e.g., 
antibody avidity, has been identified as a determining factor of efficacy. Although B lymphocytes represent 
the specialized lineage in antibody production once differentiated in plasma cells, T cells can largely 
contribute to effective and long-lasting immune responses. In fact, these cells are essential to immune 
memory, and novel vaccine targets have been identified against which T cells are likely to be the prime 
effectors. 
The stimulation of antigen-specific T cell responses requires their activation by specific antigen presenting 
cells (APCs), essentially dendritic cells (DCs), which reside in tissues or patrol through the body and are 
 
 
recruited by inflammatory signals to the site of infection. When exposed to pathogens, immature DCs will 
phagocyte and process them proteolytically, so that some pathogen components can be loaded on Major 
Histocompatibility Complex (MHC) class II molecules. DCs then undergo maturation, modulate specific 
surface receptors and migrate towards secondary lymph nodes, where the trigger of T and B cell responses 
occurs.  
The central role for mature DCs in the activation of vaccine responses reflects their unique ability to provide 
both antigen-specific and co-stimulation signals to T cells. In fact, T cells require at least two signals to 
become fully activated: 
 
1. a first antigen-specific signal provided through the T cell receptor which interacts with the        
antigen peptide-loaded MHC class II molecules on the surface of the APCs; 
2. a second antigen-unspecific signal, a co-stimulatory incentive, provided by the interaction between 
co-stimulatory molecules expressed on the membrane of the APC upon maturation with its 
counterparts on the T cell.  
 
APCs can also secrete cytokines that are sensed by the interacting T cell and determine its further phenotype 
(Th1, Th2, Th17). 
The very first requirement to elicit vaccine responses is thus to provide sufficient stimuli through vaccine 
antigens and eventually adjuvants, to trigger an inflammatory reaction that is mediated by cells of the innate 
immune system4.  
In general, the antibody response to bacterial polysaccharides is poorly affected by adjuvants, IgM 
represents the major class of antibodies induced and since their immune response does not induce memory, 
it is not boosted by subsequent immunizations. 
These characteristics are due to the fact that, unlike proteins that are T-cell dependent (TD) antigens, 
polysaccharides are T-cell independent (TI) antigens as they do not require T-cell activation for the 
induction of specific B-cell (antibody) responses. Polysaccharide antigens directly activate polysaccharide- 
specific B cells which differentiate then into plasma cells to produce antibodies, but memory B cells are not 
formed; moreover a pre-existing memory B-cell pool can be depleted by immunization with unconjugated 
polysaccharide, with risk of hypo-responsiveness on subsequent immunizations5. 
Differently from polysaccharides, proteins are TD antigens; following interaction with antigen-presenting 
cells (APC) like dendritic cells, macrophages and B-cells, protein antigens are internalized and processed 
into small peptides which are then re-exposed and presented to T lymphocytes in association with the MHC 
class II molecules. Interaction with T cells induces B cells to differentiate into plasma cells and memory B 
cells, thus initiating downstream adaptive immune responses. Unlike TI antigens, TD antigens are 
immunogenic early in infancy, the immune response induced can be boosted, enhanced by adjuvants and is 
characterized by antibody class switch and production of antigen-specific IgG. 
 
 
1.2. Polysaccharide vaccines 
Polysaccharides are important virulence factor especially for encapsulated bacteria that present on their 
surface complex carbohydrate structures. Surface polysaccharides have several functions: 
 
• in some cases they protect microorganisms from desiccation when they are exposed to the external 
environment (an  example is the hyaluronic capsule of Group A Streptococcus, whose adhesive 
properties help the pathogen to invade the host); 
•  other capsular polysaccharides prevent the activation of the alternative complement pathway; 
•  sometimes they mimic molecules produced by human cells so that the pathogen is not recognized as 
foreign by our immune system (serogroup B meningococcal capsular polysaccharide, hyaluronic 
acid).   
 
Around 1930s the protective role of antibodies (Abs) induced by pneumococcal polysaccharide started to be 
investigated and in 1945 the first vaccine composed by purified polysaccharides from selected 
pneumococcal serotypes was tested in humans6. 
The research on vaccines development was subsequently slowed down by the introduction of antibiotics, 
however, with the emergence of drug resistant strains, the development of polysaccharide vaccines started 
again and a number of them have been studied in large clinical studies. Polysaccharide vaccines against 
meningococcus serogroup ACWY, Streptococcus pneumoniae and Haemophilus influenzae type b were 
licensed between the seventies and the eighties.7,8 These bacteria possess polysaccharides which are either 
polymers formed by one monosaccharide unit (homopolymers) or more complex oligosaccharide repeats 
(heteropolymers), that can be charged or neutral.  
Polysaccharide vaccines however did not completely solve the problem of bacterial diseases caused by 
encapsulated microorganisms. Being T-cell independent antigens, one of their main features which emerged 
from clinical trials, was their scarce immunogenicity in children less than two years of age.9-10 As a 
consequence, polysaccharide vaccines can be used in adults, but not in infancy and elderly which are the 
most sensitive target populations. 
 
1.3. Glycoconjugate vaccines  
Glycoconjugate vaccines are among the safest and most efficacious vaccines developed during the last 30 
years. They are a potent tool for prevention of life-threating bacterial infectious disease like meningitis and 
pneumonia.   
The limitation of polysaccharides vaccines has been overcome by covalent conjugation to a carrier protein 
as source of T-cell epitopes. Since 1929, it has been demonstrated by Avery and Goebel that non-
 
 
immunogenic sugars after conjugation to a carrier protein become able to induce antibodies in animal 
model.11 However the first application of this concept to a vaccine for human use started only in 1980 with 
the development of the first conjugate vaccine against Haemophilus influenzae type b (Hib) that was later on 
licensed between 1987 and 1990.12-13  
Many other glycoconjugate vaccines have been developed against bacterial pathogens such as Neisseriae 
meningitidis, Streptococcus pneumoniae and Group B Streptococcus. Glycoconjugate vaccines are currently 
used in the immunization schedules of different countries like for example the United States (US) (Table 
1.1).14-20  
 
Table 1.1. Licensed glycoconjugate vaccines. 
 
PRP-TT Sanofi-Pasteur
PRP-OMPC Merck
PRP-CRM 197 Pfizer
Hib-CRM 197 GSK
MenC/Hib-TT GSK
MenA-TT Serum Institute India
MenC-CRM 197 Pfizer, GSK
MenC-TT Baxter
MenACWY-DT Sanofi-Pasteur
MenACWY-CRM197 GSK
MenACWY-TT Pfizer
7 valent-CRM197 (4, 6B, 9V, 14, 18C, 
19F, 23F) Pfizer
13 valent-CRM197 (1, 3, 4, 5, 6A, 6B, 
7F, 9V, 14, 18C, 19A, 19F, 23F) Pfizer
10 valent-DT/TT Protein D (1, 4, 5, 6B, 
7F, 9V, 14, 18C, 19F, 23F) GSK
Haemophilus influenzae 
type b/Neisseria 
meningitidis group C
Neisseria meningitidis 
serogroups ACW135Y
Streptococcus pneumoniae 
serotypes
Vaccine indication Type of conjugate Manufacturer
Haemophilus influenzae 
type b
 
 
Chemical conjugation of polysaccharides to protein carriers allows processing of the protein carrier by 
polysaccharide-specific B cells and presentation, on their surface, of the resulting peptides in association 
with MHC class II. Further interaction with carrier-specific cells then induces a TD response already early 
in life which leads to immunological memory and boosting of the response by further doses of the vaccine 
(Figure 1.1). Recently it has been proposed a novel mechanism according to which internalization of 
glycoconjugate and following proteolytic digestions generate glycopeptides which are re-exposed by MHC 
 
 
class II (Figure 1.2). This model was confirmed by isolation of specific T-cell clones directed to the sugar. 
This observation proves that although glycoconjugates are safe and effective, their mechanism of function is 
still not totally understood. 
 
Figure 1.1. Mechanism of action of a glycoconjugate vaccine.5 
 
 
Figure 1.2. Recent working model of action of a glycoconjugate vaccine.98 
 
To prepare glycoconjugate vaccines, two main approaches based on different chemistry of conjugation, have 
been used so far. One is based on the random chemical activation of the saccharide chain followed by 
covalent binding with the protein carrier obtaining a cross-linked structure between the polysaccharide and 
the protein. A second approach is based on the generation, by controlled fragmentation of the native 
polysaccharide, of appropriately sized oligosaccharides which are then activated at their terminal groups, 
usually with a linker molecule, and subsequently conjugated to the carrier protein obtaining a radial 
structure (Figure 1.3). Depending on the conjugation chemistry employed, a chemical spacer can be used in 
order to facilitate the coupling of the protein to the saccharide antigens and, in some cases, conjugation 
chemistry also requires prior derivatization of the protein carriers. 
 
 
 
Figure 1.3. Structures of glycoconjugates. 
  
In this second approach, utilization of chemically or chemo-enymatically synthesized carbohydrates, 
prepared starting from suitable monosaccharides, is increasingly attractive.21-25 Synthetic oligosaccharides 
offer the advantage of being pure and well-defined molecules, tipically bearing at the terminal residue a 
linker for coupling to protein carriers. 
A new approach called bioconjugation based on glyco-engineering the bacterial N-glycosylation pathway in 
bacteria such as Escherichia coli is also emerging. The polysaccharide, encoded by the inserted genes, is 
produced on a polyisoprenoid carrier and then is transferred to an asparagine residue of the carrier protein 
which has to contain at least one (native or engineered) N-glycosylation site. 26-29  
A chemistry which results in the formation of cross-linked structures was used for commercial Hib 
conjugate vaccines by Sanofi-Pasteur, Merck and Pfizer.  
Novartis Vaccines (NVD, now GSK Vaccines) has instead developed a conjugation chemistry which 
provides conjugates having oligosaccharides oriented radially from the carrier protein.5, 12  
In particular Hib and meningococcal NVD conjugate vaccines are made starting from purified capsular 
polysaccharides which have been size reduced by acid hydrolysis and fractionated to select an intermediate 
chain length population. The oligosaccharides were then derivatized at their reducing termini introducing 
first a primary amino group by reductive amination followed by a 6-carbon atom flexible hydrocarbon 
spacer having a terminal active ester ready for conjugation.14,30-31 The same technology was used by NVD to 
develop its quadrivalent A, C, W135, Y anti-meningococcal conjugate vaccine.32 
 
 
 
 
 
1.4. Variables influencing the immunogenicity and physicochemical properties of glycoconjugate 
vaccines  
Many aspects can influence the immunogenicity of conjugate vaccines and the main variables investigated 
so far are the size of the saccharide moiety, the saccharide:protein ratio in the purified conjugate, the 
conjugation strategy, the nature of the spacer and the protein carrier.  
Immunogenic epitopes involved in the interaction with specific antibodies usually comprise precise glycan 
structures, often not longer than six or eight sugar units (45 year-old paradigm established by Kabat).33 An 
early study by Seppälä and Mäkelä investigated the effect of saccharide size and saccharide:protein ratio on 
the immunogenicity of dextrans-protein conjugates, and found that dextrans of low molecular weight 
conjugated to chicken serum albumin induced strong anti-dextran responses in mice, while increasing the 
dextrans size resulted in reduced immunogenicity.34 Peeters et al. showed that a synthetic tetramer of Hib 
capsular polysaccharide repeating unit, conjugated to a protein carrier, induced in adult mice and non-human 
primates antibody levels comparable to a commercial Hib conjugate and higher than those induced by a 
trimer, indicating that for Hib a minimum of eight sugars is needed for a proper immunological response.35 
Laferriere et al. found little influence of the carbohydrate chain length on the immunogenicity of 
pneumococcal conjugate vaccines in mice.36 Pozsgay et al. studied the immunogenicity in mice of synthetic 
Shigella dysenteriae type 1 LPS oligosaccharides conjugated to human serum albumin (HSA). The authors 
found that octa-, dodeca-, and hexadecasaccharide fragments induced high levels of lipopolysaccharide 
binding IgG antibodies in mice after three injections and were superior to a tetrasaccharide conjugate. The 
influence of the carbohydrate:protein ratio was different for the three conjugates. The octasaccharide-HSA 
conjugate with the highest density evoked a good immune response, while in the case of dodeca- and 
hexadecasaccharide conjugates, the median density was optimal.37 
These studies suggest that oligosaccharide chain length and hapten loading are interconnected in 
determining the immunogenicity of glycoconjugate vaccines and are case antigen specific parameters.  
The spacer is a short linear molecule that is generally linked to the polysaccharide chain or to the protein or 
to both moieties, depending on the chemistry, used to facilitate the coupling between the protein and sugar. 
There are evidences in the literature which suggest that rigid, constrained spacers, like cyclohexyl 
maleimide, elicit a significant amount of undesirable antibodies, with the risk of driving the immune 
response away from the targeted epitope on the hapten.38, 39 The use of a flexible alkyl type maleimido 
spacer has been reported as a way to overcome the previous observed immunogenicity of cyclic maleimide 
linkers.40  
A number of protein carriers have been used so far in preclinical and clinical evaluation of conjugate 
vaccines.19, 41-46 Proteins such as diphtheria and tetanus toxoids, which derive from the respective toxins after 
chemical detoxification with formaldehyde, were initially selected as carriers because of the safety track 
record accumulated with tetanus and diphtheria vaccination. CRM197, a non-toxic mutant of diphtheria 
toxin47 which instead does not need chemical detoxification, has been extensively used as carrier for 
 
 
licensed Hib, pneumococcal, meningococcal conjugate vaccines and for other vaccines being developed. An 
outer membrane protein complex of serogroup B meningococcus has been used by Merck as carrier for their 
Hib conjugate vaccine.48 GSK in their multivalent pneumococcal conjugate vaccine introduced the use of 
the Hib-related protein D as carrier for most of the polysaccharides included into the vaccine.49, 50 The team 
of John Robbins made extensive use of the recombinant non-toxic form of Pseudomonas aeruginosa exo-
toxin as carrier for Staphylococcus aureus type 5 and 8 as well as for Salmonella typhi Vi conjugates.51, 52  
A number of clinical trials have been conducted to compare the immunogenicity of different conjugate 
vaccines with different carrier proteins.53-57  
It is however very difficult a direct comparison of the effect of different protein carriers, due to the 
coexistence of other variables as conjugation chemistry, saccharide chain length, adjuvant, formulation 
technology, and previous or concomitant vaccination with other antigens. 
 
1.5. Chemical biology approaches to designing defined carbohydrate vaccines 
As isolated polysaccharides are structurally complex, the corresponding glycoconjugates most likely contain 
the ‘‘right’’ B cell epitopes needed to confer protective immunity. Identification of the right epitope is a 
time-consuming step. Antigen design has traditionally been an iterative process. Understanding the structure 
of a protective B cell epitope is vital before immunization experiments are performed. The currently 
available tools to map carbohydrate epitopes can make use of small amounts of glycans for screening 
purposes. 
B cell epitopes can be classified into two groups: sequential (continuous) epitopes and conformational 
(discontinuous) epitopes. A sequential B cell epitope is recognized as the primary structure of an antigen, 
while a conformational B cell epitope consists of residues that may be distantly separated in the primary 
structure and are recognized due to the close proximity within the folded 3D structure58. The nature of an 
epitope is of utmost importance during antigen design: conformational epitopes are associated with a distinct 
secondary structure of the glycan, a feat that may only be achieved in longer sequences comprising multiple 
repeating units. Thus, the synthetic effort compromises the applicability of these long glycans as synthetic 
antigens.  
The implications of structural requirements are still poorly understood. In addition to glycan length, 
important determinants for the viability of a carbohydrate antigen comprise the stereochemistry of 
glycosidic linkages and the arrangement of individual glycan components within a repeating unit. In 
addition, the presence of branching points and different substituents like phosphates, acetates and pyruvates 
may be crucial for immunogenicity59. 
Recent progress in synthetic carbohydrate chemistry, bioinformatics and analysis of carbohydrate-protein 
interactions facilitates the 3D-structural interpretation of glycan-antibody complexes. Numerous methods 
are currently in practice that can aid the antigen design process. For instance, advancements in structural 
 
 
methods, such as X-ray crystallography, NMR or small angle X-ray scattering (SAXS), are used to generate 
valuable information on the 3D structures of glycans and their interaction partners60-62. Information on the 
structural requirements of glycan recognition can form the basis of designing optimized carbohydrate 
vaccine candidates. Structural vaccinology is a newly emerging field and has already contributed 
significantly to the development of modern protein-based vaccines63-64. Adaptation of the structural 
vaccinology principles to saccharides may reveal the nature of glycotopes that are recognized by the host 
immune system, thereby facilitating the design of more efficient vaccines. For instance, structural 
understanding of the epitope helps to improve biochemical characteristics of vaccine antigens and to select 
the combination of glycan residues that are necessary to increase the breadth of the immune response. 
Recently, Bundle and coworkers used structural information to design a universal carbohydrate antigen 
based on the antigenic determinants of A-type and M-type O antigens of Brucella65. Studies on the nature of 
antigenic determinants recognized by monoclonal antibodies facilitated the design of one single 
oligosaccharide that may form the basis for the diagnosis of Brucellosis.  
Structural information on the binding of epitopes may help in decoding the rules of immunodominance and 
provide the basis for manipulating the antigen structure to render protective epitopes immunodominant64. 
3D-structural information on oligosaccharide antigens is becoming increasingly available. NMR 
spectroscopy and X-ray crystallography are the most reliable techniques to reveal glycan-antibody 
interactions at the molecular level. However, typical Ka values of glycan-antibody interactions are weak, in 
the 102–106 M range, complicating the cocrystallization of both binding partners. In such instances, NMR is 
extremely useful to obtain insights into the solution structure and the dynamics of a ligand-antibody 
complex. However, due to the intrinsic complexity and flexibility of carbohydrates, a multidisciplinary 
strategy combining NMR parameters with molecular modeling protocols should be followed in order to 
generate reliable structural information66. 
In ligand-based structural glycobiology, changes in the parameters of the ligand are monitored upon passing 
from the free to the bound state66. Thereby, NMR techniques are often preferred over other biophysical 
methods. 
NMR measurements can be employed to detect binding, to elucidate the bound conformation of the glycan, 
to map the bound epitope and to provide information on molecular dynamics66. Combinations of transferred 
nuclear Overhauser effect spectroscopy (TR-NOESY)67 and saturation transfer difference (STD)68-69 NMR 
experiments have been employed extensively to study the conformations of carbohydrates bound to 
antibodies and to define interacting epitopes61, 70-73. Seeberger group revealed the structural features of the 
interaction between a Bacillus anthracis tetrasaccharide containing three rhamnoses and a unique terminal 
anthrose unit and a monoclonal antibody by STD NMR. A combined approach involving glycan array 
screening, surface plasmon resonance (SPR) and STD NMR revealed structural insights into the molecular 
events of carbohydrate-antibody interactions. The use of several B. anthracis oligosaccharides demonstrated 
a crucial role of the anthrose residue in recognition73. 
 
 
A shortcoming of NMR-based epitope mapping is the restriction on certain tight kinetic requirements. Such 
methods work optimally when the off rate is fast in the relaxation time scale of the ligand. For slow 
dissociation kinetics, conventional NMR methods do not provide adequate information. Consequently, STD 
and TR-NOESY methods are not useful for dissociation constants in the low micromolar or nanomolar 
ranges66 and the observation of the parameters associated with the receptor becomes the method of choice. 
In a receptor-based approach, methods of structural biochemistry are employed to map the antigen 
combining sites or complementarity determining regions (CDRs) of an antibody. However, antibodies are 
large macromolecules and, due to their weaker interactions, gaining detailed structural information of a 
carbohydrate-antibody complex represents a real challenge.  
X-ray crystallography would provide structural information on antigen combining sites with highest 
resolution. Despite the usefulness of this approach, only few crystal structures of carbohydrate-antibody 
complexes have been solved thus far. Due to the high polarity of the hydroxyl groups and flexibility of the 
carbohydrate structures74, crystallization of carbohydrate-protein complexes is a challenging task. Infact for 
example, conformational and compositional heterogeneity in carbohydrate moieties of glycoconjugates is 
expected to interfere with crystallization, and deglycosylation has proved essential for heavily glycosylated 
proteins such as human chorionic gonadotropin75.  
Various studies have demonstrated that carbohydrate binding sites of an anti-glycan antibody can vary 
significantly in the epitope size they accommodate. Cocrystal structures of carbohydrate-bound antibodies 
reveal the span of the bound epitope and structural details of important residues that interact with antibody 
CDRs. Relatively small oligosaccharides occupy the binding site in reported structures76-77, while few 
reports of larger epitopes exist78. In one special case, a (2/8)-polysialic acid apparently occupies an 
exceptionally long binding site77. Two key examples demonstrating the receptor based approach in 
carbohydrate antigen design involve Vibrio cholerae O1 antigen76, where the epitope involves 2 consecutive 
residues in the terminal part of the molecule, and synthetic O antigen fragments from serotype 2a Shigella 
flexneri62, where the epitope involves 6 out of 10 monosaccharides. 
 
1.6. GBS 
Streptococcus agalactiae, also known as Group B Streptococcus (GBS), is one of the major causes of sepsis, 
pneumonia and meningitis in neonatal and infants in the first three months after birth.79 It is a Gram positive 
beta-hemolytic coccus which appears in pairs (Figure 1.4) or chains80, that colonizes the urogenital and 
gastrointestinal tracts of more than 30% of the healthy population and, in particular, the vagina of 25-40% of 
healthy women.81-83 
 
 
 
Figure 1.4. Immunogold Electron Microscopy of GBS strain CJB111.99 
 
It was classified for the first time in 1930 by R. Lancefield and R. Hare during a serological differentiation 
study on human isolates and other groups of hemolytic streptococci.84 It is included in the group B of 
“Lancefield System”, where Streptococci are identified with alphabetical letters from A to O, based on 
capsular polysaccharide antigens and groups A, B and D are the most dangerous85. GBS clinical isolates are 
also classified into ten serotypes, according to the chemical nature of capsular polysaccharides (PS): Ia, Ib, 
II, III, IV, V, VI, VII, VIII and IX.86-88 However around 8-14% of the clinical isolates in the Europe and USA 
are non-typeable strains because cannot be distinguished on the basis of PS antigenicity. All GBS serotypes 
contain, in different combinations, these carbohydrates: galactose, glucose, rhamnose, N-
acetylglucosammine and sialic acid (N-acetylneuraminic acid) (Figure 1.5).  
 
 
 
Figure 1.5. Chemical structures of isolated GBS serotypes.100 
 
 
 
Streptococcus agalactiae is known as the most frequent cause of sepsis, pneumonia and meningitis in 
neonates within first months from birth.82,89 It is an etiologic agent also in adults, in particular elderly 
persons, immunocompromised, diabetics and patients affected by others chronic pathology of liver and 
kidney. In the cellular hyper-trophism of vaginal epithelium, where it can adhere despite low values of pH90, 
it forms a permanent colonization in more than 40% of women. During pregnancy, the uro-genital tract 
colonization is cause of severe infections/year, leading to chorioamnionitis, endometrial tenderness, 
tachycardia, cystitis and fever which make necessary antibiotic therapies also after delivery. GBS can also 
be cause of intrauterine death, aborts, prelabor rupture of the membranes, with preterm labor/delivery, 
causing the exposure of 90% of premature neonates to infection. In most cases infection is transferred 
vertically from asymptomatic mothers and, every year, only for US, 8000-12000 infected babies and 2000 
deaths are recorded.  Infection appears in uterus or at delivery for contact of throat, ear, nostril, umbilicus 
and respiratory ways with amniotic liquid or infected vaginal fluids. After the aspiration/ingestion of 
bacteria, neonatal lungs become the starting focus of infection. From here it can rapidly arrive to flow of 
blood, continue towards others tissues and organs like blood-brain barrier (Figure 1.6). 
 
 
 
Figure 1.6. Stages of neonatal group B streptococcal (GBS) infection.101 
 
Neonatal disease can occur in two different forms: the Early-Onset Disease (EOD) and the Late-Onset 
Disease (LOD).  
 
EOD occurs during the first seven days of life, with the vast majority of cases (approximately 90%) present 
during the first 24 hours of life.91 Neonates with EOD present respiratory disease (54%), sepsis without 
focus (27%) and meningitis (15%).92  
 
LOD occurs beyond seven days of life and can develop up to three months of age. In 50% of the cases it has 
a maternal origin. Neonates with LOD present sepsis (46%), meningitis (37%), urinary infection (7%), 
osteoarthritis (6%), respiratory disease (4%) and cellulitis (4%). Over 20% of survivors of GBS meningitis 
have permanent sequelae, including hearing loss, mental retardation, cortical blindness and seizures (Table 
1.2).  
 
 
Table 1.2. Neonatal manifestation of group B streptococcal disease.102 
 Early-onset disease Late-onset disease 
 
Onset 
 
First week of life (usually 
within the first 24 h) 
 
One week to 3 months of 
age 
Clinical presentation Respiratory distress 
Pneumonia 
Sepsis 
Sepsis 
Meningitis 
Osteoarthritis 
Incidence of prematury Increased No change 
Maternal obstetrical 
complication 
Frequent (70%) Uncommon 
Transmission Vertical: acquired in utero 
or intrapartum 
Usually horizontal 
transmission: can also be 
intrapartum 
Predominant serotypes* Ia, III, V III, Ia, V 
*In descending order of prevalence  
 
 
Risk factors include non-white race and preterm birth, but most of time it is a horizontal transmission, after 
contact with sanitary staff or colonized mothers. LOD is basically due to serotype III strain, with an 
incidence until 60% depending on the geographic area. Studies performed on non-pregnant adults with GBS 
associated invasive disease revealed that GBS serotypes Ia, III and V accounted for more than two-third of 
cases. More than 25% of the subjects had invasive GBS disease caused by type V strains (Table 1.3).  
 
Table 1.3. Serotype distribution of group B streptococcal isolates from non-pregnant adults with 
invasive GBS infection, 1992-1999.103 
 
GBS serotype N° (%) of subjects (n=589) 
Ia 143 (24.3) 
Ib 72 (12.2) 
II 70 (11.9) 
III 97 (16.5) 
IV 2 (0.3) 
V 162 (27.5) 
VI 0 
VII  0 
VIII 1 (0.2) 
Non-typeable 42 (7.1) 
 
 
 
The clinical manifestations of GBS infection in elderly adults are: skin and soft-tissue infections (in these 
cases, cellulites is the most frequent clinical manifestation), urinary tract infections (bacteremic urinary tract 
infections account for 33.4% of the cases in adults >70 years of age), pneumoniae (only in older debilitated 
adults), bacteremia with no identified focus (in the 15% of non-pregnant adults affected by GBS invasive 
diseases), arthritis, osteomyelitis, meningitis (in only 2% of non-pregnant adults with GBS invasive disease) 
and endocarditis. 
 
1.7. GBS Vaccine 
Early in 1930s Rebecca Lancefield et al. demonstrated that polyclonal antibodies from rabbit sera, able to 
recognize PS epitopes, conferred protection against GBS infection in animal models. During the last two 
decades, plain GBS polysaccharides have been extensively studied as vaccines in preclinical and human 
clinical studies. However, the first human clinical trials conducted in the 1980s showed that the purified 
native PS from serotype III was not sufficient to induce a robust IgG response in adults and induced an 
insignificant response in neonates.  
Subsequently, conjugation of PSs to immunogenic proteins, such as tetanus toxoid (TT) and mutated 
diphtheria toxoid (CRM197)93-94, was shown to dramatically increase the immune response in children, 
eliciting the differentiation of memory cells associated to a long term protection. Following these findings, 
PS-TT conjugate vaccines based on nine GBS serotypes were produced and tested pre-clinically.76 These 
studies, carried out in animal models, showed that conjugate antigens were able to induce functional PS-
specific IgG that, in presence of complement, stimulate in vitro the opsonization and killing of GBS by 
human peripheral blood leukocytes. This success constituted the rationale to proceed with the clinical 
studies in human. Further studies demonstrated that glycoconjugate vaccines constituted by serotypes Ia, Ib, 
II, III, and V PS linked to TT were safe, well-tolerated and highly immunogenic in human adults94, but cross-
protection between serotypes was still lacking. Therefore a multivalent vaccine was required in order to 
obtain a broad coverage of the vaccine against the prevalent circulating GBS serotypes. A tetravalent 
combination of PS–TT conjugates (serotypes Ia, Ib, II, and III) was successfully tested in a mouse model and 
further human trials were performed using the combination of two PS TT-conjugates (serotypes II and III). 
Results showed that the combination had the same immunogenicity and reactogenicity of each monovalent 
PS vaccine.94  
However, although recent epidemiological studies95 suggest that a tetravalent combination of serotypes Ia, 
Ib, III and V would be sufficient to achieve a coverage against the majority of GBS strains circulating in 
Europe and North America, there are other geographical areas where such combination would be not be 
effective owing to a different serotypes distribution (i.e. VI and VIII, predominant in Japan). Moreover, the 
PS-conjugate vaccine would not protect against all the non-typeable isolates.  
 
 
An additional obstacle to the licensure of vaccine against GBS is the difficulty of conducting clinical 
efficacy trials in human: large sample size would be required, but the use of IAP reduces the incidence of 
neonatal disease. A possible solution to overcome this difficulty came from the studies of Feng-Ying C. Lin 
and coworkers who carried out a prospective way to estimate the maternal GBS-PSs antibody levels needed 
to give protection to neonates from EOD. The amount of maternal antibodies against GBS-PSIa was 
measured by ELISA in 45 case patients (mothers whose neonates developed EOD) and 319 controls 
(mothers of neonates colonized by GBS-PSIa but without EOD). Distribution of maternal antibody 
concentrations showed that the probability of developing EOD declined with increasing maternal levels of 
anti-PSIa IgG96. This work demonstrated that it is possible to define thresholds of anti-GBS PSIa specific 
IgG levels in the mothers which are predictive for the protection of newborns.  
More recently, thresholds have also been set for the levels of maternal anti GBS-PSIII IgGs required to 
protect newborns from EOD caused by GBS serotype III.97 The results of Feng-Ying C. Lin suggested that 
complex clinical trials required for a GBS vaccine registration might be replaced with an in vitro correlate of 
protection based on the quantification of vaccine induced antibodies.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1. Isolation and purification of the type III capsular polysaccharide 
GBS strain COH1 was used for preparation of PSIII from 1L of bacterial culture grown to exponential phase 
in Todd Hewitt broth. The purification process was based on previously described procedures1. Briefly, the 
bacterial pellet was recovered by centrifugation at 4000 rpm for 20 min and incubated with 0.8 N NaOH at 
37 °C for 36h. After centrifugation at 4000 rpm for 20 min, 1M Tris buffer (1:9, v/v) was added to the 
supernatant and diluted with 1:1 (v/v) HCl to reach a neutral pH. To further purify PSIII, 2 M CaCl2 (0.1 M 
final concentration) and ethanol (30% (v/v) final concentration) were added to the solution. After 
centrifugation at 4000 × g for 20 min, the supernatant was subjected to tangential flow filtration with a 10 
kDa-molecular weight cutoff (Hydrosart Sartorius) against 14 volumes of 50 mM Tris, 500 mM NaCl pH 
8.8 and 7 volumes of 10mM sodium phosphate pH 7.2.  
 
2.2. Fragments of type III polysaccharides prepared by deamination 
Native type III PS was partially de-N-acetylated as follows: the polysaccharide was dissolved at 2 mg/mL in 
0.5 M NaOH, heated at 70°C for 2-4h, and then chilled in an ice-water bath. Glacial acetic acid was added to 
the sample to bring the pH to 4.5. The partially de-N-acetylated product was deaminated by the addition of 
200µL of 5% (w/v) NaNO2 and stirred at 4°C for 2h. The material was purified by a G25 column eluting 
with water. 
To reconstitute full N-acetylation of sialic acid residues, a 1:1 diluted solution of 4.15µL/mL acetic 
anhydride in ethanol was added, and the reaction was incubated at room temperature for 2h. The material 
was purified by a G25 column eluting with water. 
 
2.3. Purification of oligosaccharides 
The fragments of different length were separated by anion exchange chromatography using a semi-
preparative HPLC with a Mono Q column. Increasing the NaCl percentage of the elution buffer with a 
staircase gradient, it was possible to isolate oligosaccharides with a difference in chain length in the range of 
1-2 repeating units. 
 
2.4. MALDI analysis 
MALDI-TOF mass spectra were recorded by UltraFlex III MALDI-TOF/TOF instrument (Bruker Daltonics) 
in linear mode and with negative ion detection. The samples for analysis were prepared by mixing 2.5µL of 
 
 
product (~10µM) and 2.5µL of Super DHB matrix. 2.5µL of each mixture were deposited on samples plate, 
dried at room temperature for 10 min and subjected to the spectrometer. 
 
2.5. HPAEC-PAD analysis for revealing Gal, Glc and GlcNAc 
Standard samples of GBS PSIII at five increasing concentrations ranging between 0.5 and 10.3µg/mL were 
prepared to build the calibration curve. GBS PSIII samples were prepared targeting the calibration curve 
midpoint. The reference and analytical samples were prepared in 4 M trifluoroacetic acid, incubated at 
100°C for 3h, dried under vacuum (SpeedVac Thermo), and suspended in water. All analytical samples were 
filtered with 0.45 µm Phenex-NY (Phenomenex) filters before analysis. HPAEC-PAD analysis was 
performed with a Dionex ICS-3000 equipped with a CarboPac PA1 column (4 × 250 mm; Dionex) coupled 
with a PA1 guard to column (4 × 50 mm; Dionex). Samples (50 µL injection volume) were run at 1mL/min, 
using isocratic elution with 14 mM NaOH, followed by a washing step with 0.5 M NaOH.  
 
2.6. HPAEC-PAD analysis for revealing NeuNAc 
The calibration curve was prepared with five increasing concentrations of NeuNAc ranging between 1.0 and 
10.0 µg/mL (as saccharide powder/mL). GBS PSIII samples were prepared targeting the calibration curve 
midpoint. The reference and analytical samples were prepared in 50 mM HCl, incubated at 75°C for 1h, and 
treated with 62.5 mM NaOH after chilling at +4°C. All analytical samples were filtered with 0.45 µm 
Phenex-NY (Phenomenex) filters before analysis. HPAEC-PAD analysis was performed with a Dionex ICS-
3000 equipped with a CarboPac PA20 Fast Sialic Acid column (3 × 30 mm; Dionex), 5µL injection volume 
and 0.5mL/min flow, using elution from 30 mM to 500 mM sodium acetate.  
 
2.7. HPAEC-PAD data acquisition and analysis 
In both HPAEC-PAD analyses, the effluent was monitored using an electrochemical detector in the pulse 
amperometric mode with a gold working electrode and an Ag/AgCl reference electrode. A quadruple-
potential waveform for carbohydrates was applied. The resulting chromatographic data were processed 
using Chromeleon software 6.8 (Dionex). Gal, Glc, GlcNAc and NeuNAc concentration were determined 
and converted in µmol/mL to estimate the relative mol/mol ratio. 
 
 
 
 
 
2.8. CRM197 conjugation of PSIII oligosaccharides obtained by chemical depolymerization 
For the conjugation reaction to CRM197, purified oligosaccharides from chemical depolymerization were 
dissolved in 100 mM sodium phosphate buffer at pH 7.2. CRM was added to the solution with an active 
ester to protein molar ratio varying from of 10:1 to 70:1 and a final concentration of 10mg/mL in protein. 
Then, NaBCNH3 was added to the solution (saccharide:NaBCNH3 1:1 w/w) and incubated ON at 37°C. 
Conjugation was monitored by SDS-PAGE 4−12% of polyacrylamide in MOPS. The conjugates were 
purified from the unreacted saccharide on a CHT hydroxyapatite column, using for elution 2 mM sodium 
phosphate/300mM NaCl at pH 7.2 (20mL, 1mL/min), followed by 400 mM sodium phosphate at pH 7.2 
(40mL, 1mL/min). When unreacted CRM197 was present, the conjugate was purified by CHT hydroxyapatite 
column chromatography using a 4 step elution program: 2 mM sodium phosphate/300mM NaCl at pH 7.2 
(20 mL, 1 mL/min), 10 mM sodium phosphate at pH 7.2 (20mL, 1mL/min), 35 mM sodium phosphate at pH 
7.2 (20mL, 1mL/min), and 400 mM sodium phosphate at pH 7.2 (40mL, 1mL/min). The conjugate was 
detected by measuring UV absorption at 215, 254 and 280 nm. Protein content in the purified 
glycoconjugates was determined by micro-BCA (Thermo-scientific). Saccharide content was estimated by 
HPAEC-PAD analysis. 
 
2.9. CRM197 conjugation of synthetic DP1s 
A solution of di-N-hydroxysuccinimidyl adipate (10 eq) and triethylamine (0.2 eq) in DMSO was added to 
the pentasaccharide 1-3. The reaction was stirred for 3h, then the product was precipitate at 0°C by adding 
ethyl acetate (9 volumes). The solid was washed 10 times with ethyl acetate (2 volumes each) and 
lyophilized. The activated sugar was conjugated to CRM197 in sodium phosphate 100 mM at a protein 
concentration of 5mg/ml, using a ratio of 50-100:1 mol saccharide/mol protein.  
 
2.10. SDS-PAGE analysis 
Sodium Dodecyl Sulfate- Polyacrilamide gel electrophoresis (SDS-PAGE) was performed on 4-12% pre-
casted polyacrylamide gel (NuPAGE®Invitrogen) using MOPS 1x as running buffer 
(NuPAGE®Invitrogen). 5µg of protein were loaded for each sample. After electrophoretic running with a 
voltage of 150V for about 45 minutes, the gel was stained with blue coomassie.  
 
2.11. Desialylation of PSIII-CRM197 conjugates 
3mg of PSIII-CRM197 as saccharide content (Saccharide Concentration 984.6 µg/mL, Protein Concentration 
757.4 µg/mL, Glycosylation Degree 1.30) were dried under vacuum (Genevac EZ-2 Plus) and re-dissolved 
 
 
in 3mL of deuterated sodium acetate 50 mM at pH 4.75; the mixture was reacted at 80°C and monitored by 
1H NMR to estimate the de-sialylation percentage of each sample.  
The conjugates were purified by dialysis against 10 mM sodium phosphate pH 7.2 and characterized for 
their Gal content, protein concentration and integrity (SDS-Page analysis and Capillary Electrophoresis 
analysis). 
 
2.12. Immunogenicity of conjugates in mice 
Two groups of eight female BALB/c mice were immunized by intraperitoneal injection of different doses in 
saccharide content of each prduced glycoconjugate using alum hydroxide as an adjuvant. Alum hydroxide 
and CRM-PSIII were used as controls. Mice received the vaccines at days 1, 21 and 35. Sera were bled at 
days 1, 21, 35 and 49. 
 
2.13. ELISA analysis using GBS PS III conjugated to human serum albumin (HSA) as coating reagent 
Microtiter plates (96 wells, NUNC, Maxisorp) were coated with 100 µL of 1µg/mL of GBS PSIII conjugated 
to HSA via the spacer adipic acid dihydrazide in Phosphate Buffered Saline (PBS) pH 7.4. Plates were 
incubated overnight at 2-8°C, washed three times with PBST (0.05% Tween-20 in PBS pH 7.4) and 
saturated with 250 µL/well of PBST-B (2% Bovine Serum Albumin-BSA in PBST) for 90 min at 37°C. The 
plates were then aspirated to remove the solution. Two-fold serial dilutions of test and standard sera in 
PBST-B were added to each well. Plates were then incubated at 37°C for 1h, washed with PBST, and then 
incubated for 90 min at 37°C with anti-mouse IgG-alkaline phosphatase (Sigma) diluted 1:2000 or anti-
rabbit IgG-alkaline phosphatase diluted 1:1000 in PBST-B. After washing, the plates were developed with a 
4 mg/mL solution of p-Nitrophenyl Phosphate (pNPP) in 1 M diethanolamine (DEA) pH 9.8, at room 
temperature for 30 min. After blocking with 7% EDTA, the absorbance was measured using a 
SPECTRAmax plate reader with wavelength set at 405 nm. IgG concentrations were expressed as relative 
ELISA Units/mL (EU/mL) and were calculated by interpolating the absorbance values of serial sample 
dilutions on the standard calibration curve (Reference line method). The murine standard consists of a pool 
of hyperimmune sera obtained from animals immunized with 3 doses of GBS PS III-CRM conjugate 
vaccines adjuvanted with Alum. 
ELISA inhibition experiments were performed following the same procedure but pre-incubating sera with 
one or more concentrations of the inhibitor for 20 min at room temperature. 
 
 
 
 
 
2.14. ELISA analysis using unconjugated PSIII or Pn14 as coating reagent 
Microtiter plates (96 wells, NUNC, Maxisorp) were coated with 100 µL of unconjugated PS III or Pn14 in 
PBS pH 7.4 (35µg/mL), followed by overnight incubation at 2-8°C. After washing three times with PBST, a 
PBS solution containing 2% BSA and sucrose (51 mg/mL) was added (250 µL/well), and plates were 
incubated 90 min at 37°C, and then aspirated to remove the solution. Two-fold serial dilutions of test and 
standard sera in PBST-B were added to each well. Plates were then incubated at 37°C for 2 hours, washed 
with PBST, and incubated for 2 additional hours at 37°C with either anti-mouse IgG-alkaline phosphatase 
(Sigma) diluted 1:2000 or anti-rabbit IgG-alkaline phosphatase diluted 1:1000 in PBST-B. After washing, 
the plates were developed with pNPP and the absorbance values measured with a SPECTRAmax plate 
reader as reported in the previous section. IgG concentrations were calculated as reciprocal serum dilution 
giving OD of 1.0. 
 
2.15. Opsonophagocytosis Killing Assay (OPKA) 
Functional activity of anti-GBS antibodies was estimated by Opsono Phagocytic Killing Assay (OPKA) 
using differentiated HL-60 cells and strains COH1-III2. The percent of killing was calculated as (mean 
Colony Forming Units at T0 - mean CFU at T60)/(mean CFU at T0). OPK titers were expressed as the 
reciprocal serum dilution mediating 50% bacterial killing, estimated through piecewise linear interpolation 
of the dilution-killing OPK data. The Lower Limit of Detection was 1:30 and the assay coefficient of 
variation was approximately 30%. 
OPK inhibition experiments were performed following the same assay but pre-incubating sera with one or 
more concentrations of the inhibitor for 20 min at room temperature. 
 
2.16. Preparation of anti-PSIII rabbit monoclonal antibody 
The clone producing the rabbit monoclonal antibody anti-PSIII NVS-1-19-5 was obtained using hybridoma 
technology by EPITOMICS Inc. (California). Rabbits were immunized five times with GBS PSIII-CRM 
conjugate. At the time of each injection, the antigen aliquot was thawed and combined with Complete 
Freund's Adjuvant (CFA) (for the first injection) or with incomplete Freund’s Adjuvant (IFA) for the 
subsequently injections. The injection route was subcutaneous (SC). The serum titer against PSIII was 
evaluated and one rabbit was chosen. After splenectomy two hundred million lymphocyte cells were fused 
with 100 million fusion partner cells and plated on 20x 96-well plates respectively. Cell growth was 
examined 2-3 weeks after fusion. Supernatants were screened by ELISA against PSIII-HSA and 9 positive 
multiclone supernatants were analyzed by OPK assay for the functional activity. 3 clones were sub-cloned 
and supernatants analyzed as described above. From the selected hybridoma clone IgG heavy and light chain 
 
 
cDNA was amplified, cloned into proprietary mammalian expression vector and sequenced. Then, transient 
expression of recombinant antibody in HEK-293 derived cell line was performed and the recombinant rabbit 
mAb obtained was purified using protein A from the transfection supernatant. Rabbit mAb obtained was 
analyzed by ELISA against PSIII-HSA to confirm specific binding and by OPK assay for functional activity. 
 
2.17. Fab production 
Fab was prepared from the mAb using a “Fab Preparation Kit” (Pierce). mAb was digested into Fab by 
incubation overnight in a buffer containing immobilized papain in a hot room at 37°C. The resultant soluble 
Fab, Fc fragments and undigested IgG were separated from the immobilized papain gel by a separator tube. 
Then the Fab was separated from the Fc and undigested IgG by using a protein A column. Fab solution was 
exchanged using Zeba Spin Desalting column in PBS pH 7.2. 
 
2.18. Surface Plasmon Resonance (SPR) analysis 
Binding kinetics and affinities were determined by SPR using a BIACORE X100 system. Glycoconjugates 
of PSIII and its fragments were immobilized on research grade CM5 sensor chips (Biacore) using the amine 
coupling kit supplied by the manufacturer (Biacore). Immobilizations were conducted in 10-20mM sodium 
acetate (pH 4-5) at sugar concentrations of 2-4µg/mL. The immobilized surface density was ~50 resonance 
units in each instance. Measurements were conducted in 10 mM HEPES (pH 7.2), 150mM NaCl, 3mM 
EDTA, 0.005% Tween20 at 25°C and at a flow rate of 45µL/min. Following mAb or Fab binding, conjugate 
surfaces were regenerated with 3.5M MgCl2 and a contact time of 120s. Sensorgram data were analyzed 
using BIAevaluation software (Biacore). 
 
2.19. SPR Fab binding inhibition 
Inhibition assays were performed following the SPR procedure as described above using a CM5 sensor chip 
with immobilized HSA-PSIII. Binding analysis was performed with samples of Fab at a fixed concentration 
pre-incubated with PSIII or its fragments serially diluted (2x) starting from a concentration of 2mg/mL.  
 
2.20. STD NMR experiments 
NMR experiments were carried out on a Bruker 500 MHz NMR instrument equipped with a TBI cooled 
probe at controlled temperature (± 0.1 K). Data acquisition and processing were performed using TOPSPIN 
1.3 and 3.1 software, respectively. Suppression of water signal was achieved by excitation sculpting (2 msec 
 
 
selective square pulse). Proton-Carbon Saccharides resonances were assigned collecting both 1D (1H and 
13C) and 2D (TOCSY, NOESY, HSQC, HSQC-TOCSY) experiments, using standard pulse sequences. STD-
NMR experiments were acquire with 96 scans over 96 accumulations and spectral width of 8000 Hz (12 
ppm) at 298 K; a saturation transfer of 2/4 sec. were applied to enhance the saturation transfer effect, 
irradiating at a frequency of 8.0, -1.0 and -2.0 ppm (3 different spectra recorded for each sample). No 
differences were observed in the STD spectra irradiating at 8.0 or -1.0 or -2.0 ppm (4000, -500 and -1000 Hz 
respectively) for all samples, confirming that the saturation transfer effect was not irradiation dependent. To 
avoid pitfalls in the interpretation of STD-NMR spectra, a negative control spectrum was always recorded in 
absence of mAb (ligand and buffer) at the very same condition (concentration and pH) of the mAb-
saccharide samples. The STD negative controls were always subtracted to the relative mAb-saccharide STD 
spectrum, obtaining the STDD experiments. For branched pentasaccharide [α-NeuNAc-(2→3)-β-Gal-
(1→4)-β-GlcNAc-(6→1)-β-Glc-(4→1)-β-Gal] increasing saturation times from 0.5 up to 5.0 sec were 
applied to avoid overseeing of possible bias in the calculation of STD effects due to the different proton 
longitudinal relaxation times (T1), as well as the intramolecular spin diffusion within the bound state.  
 
2.21. NMR sample preparation 
 mAb were exchanged in the working buffer (Tris d-11 50 mM in D2O at pH 8.0 +/- 0.1) through 2mL Zeba 
Spin desalting column saturated with 3 cycles of working buffer, mAb were finally eluted at the same 
starting concentration of 1mg/ml. The 100% of recovery was assessed through microBCA 
spectrophotometric assay. All saccharides used [DP3, DP2, fragments 1-3 or desialylated pentasaccharide 
(DP1)] were desalted, quantified, dried and then dissolved in the working buffer too. mAb final 
concentration in the NMR tube was of 4uM. Ligand (saccharides): mAb ratios were set from 1:15 up to 
1:100 mol/mol, depending on samples. 
 
2.22. Protein crystallization 
Rabbit Fab NVS-1-19-5 was purified in 20 mM Tris·HCl, 150mM NaCl, pH 8.0, and concentrated to 20 
mg/mL using centrifugal filter devices with a 10 kDa cutoff membrane (Amicon Ultra; Millipore). The 
complex of DP2 oligosaccharide with the Fab NVS-1-19-5 was prepared by incubation at RT with a molar 
ratio saccharide/Fab 10:1. Crystallization experiments were performed using a sitting-drop vapor-diffusion 
format at 295 K, by mixing equal volumes (200 nL) of the complex with crystallization reservoir solutions 
using a Crystal Gryphon liquid handling robot (Art Robbins Instruments). Crystals were obtained after 48 
hours using a reservoir made of 0.1 M Cadmium chloride hemi (pentahydrate), 30% (v/v) PEG 400, and 0.1 
M sodium acetate, pH 4.6 (Structure Screen 1 & 2 HT-96; Molecular Dimensions). All crystals were 
mounted in cryoloops, and flash-cooled in liquid nitrogen for subsequent data collection at 100 K. 
 
 
2.23. Structure determination 
X-ray diffraction data were collected at the ESRF (Grenoble, France), on beamline ID30A-1 (MASSIF-1), 
and using a Pilatus 2M detector. Data were indexed and processed using XDS3, and the CCP4 program 
suite4. Crystals belonged to space group C2221, with the asymmetric unit containing two Fab-DP2 
complexes. The structure of the complex was determined by molecular replacement in Phaser5, using as 
template model coordinates the structure of rabbit Fab R56 (PDB code 4JO1). Refinement and manual 
model building were performed using Phenix6, BUSTER7 and COOT8. Structure quality was assessed using 
Molprobity9. Figures were generated using PyMOL (http://www.pymol.org). Data collection and refinement 
statistics are reported in Table 5.5. 
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CHAPTER 3: PREPARATION OF SYNTHETIC GBS TYPE III FRAGMENTS 
3.1. Synthesis of Group B Streptococcus type III polysaccharide fragments  
A [2 + 3] convergent approach leading to the repeating units 1-3 (called linear, branched and Y-shape DP1, 
respectively) with the end terminal sugar bearing a linker for possible conjugation has been established1. 
 
 
 
Figure 3.1. Chemical structure of PSIII and related repeating unit sequences 1-3 (linear, branched 
and Y-shape DP1, respectively). In our approach R was a linker suited for conjugation (CH2CH2NH2).  A 
[2 + 3] convergent approach was envisaged for the synthesis of these fragments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1. Chemical shift (ppm) of 1H and 13C NMR signals and 3J H1-H2 scalar coupling costants of 
linear, branched and Y-shape DP1 in D2Oa 
 
1- Linear DP1 2- Branched DP1 3- Y-shape DP1 PSIIIc 
Residue 
1H 13C 1H 13C 1H 13C 1H 13C 
Gal 
1 4.43 J 8.2 Hz 103.77 
4.45 
J 7.8 Hz 103.28 
4.39 
J 8.0 Hz 103.72 4.43 103.90 
2 3.57 70.68 3.55 71.58 3.57 70.49 3.59 70.82 
3 3.72 82.85 3.68 73.18 3.72 83.08 3.73 83.32 
4 4.16 69.05 3.93 69.48 4.16 69.16 4.17 69.06 
5 3.66 75.10 3.68 72.96 3.69 75.70 3.71 75.78 
6 3.65 63.16 3.71 61.58 3.73 62.35 3.74 61.87 
6' 3.88  3.76 
 
3.76 
 
3.79  
GlcNAc 
1 4.69 J 8.2 Hz 103.72 
4.52 
J 7.8 Hz 101.98 
4.71 
J 8.0 Hz 103.63 
4.70 
 
103.97 
2 3.81 55.89 3.75 55.68 3.80 56.08 3.83 56.01 
3 3.73 72.82 3.72 74.23 3.73 73.40 3.73 72.85 
4 3.76 78.50 3.86 77.98 3.88 78.28 3.91 77.40 
5 3.72 75.69 3.72 76.02 3.73 74.38 3.73 73.90 
6 3.95 68.18 4.00 68.18 3.97 68.51 3.98 68.22 
6' 3.95  4.31 
 
4.30 
 
4.29  
Glc 
1 4.50 J 8.5 Hz 102.74 
4.55 
J 7.8 Hz 103.00 
4.52 
J 8.0 Hz 103.66 4.54 103.44 
2 3.32 73.51 3.37 73.35 3.31 73.88 3.36 73.42 
3 3.64 75.38 3.67 75.15 3.52 76.78 3.67 75.12 
4 3.65 78.58 3.67 78.75 3.40 70.78 3.67 79.23 
5 3.66 75.38 3.68 75.54 3.53 76.58 3.67 75.53 
6 3.81 60.62 3.84 60.73 3.73 61.38 3.81 60.86 
6' 3.96  3.99 
 
3.93 
 
4.00  
Galsb 
1 4.56 J 9.0 Hz 103.00 
4.61 
J 7.6 Hz 102.78 
4.62 
J 7.8 Hz 102.95 4.62 102.87 
2 3.57 70.22 3.56 69.89 3.57 70.28 3.57 70.23 
3 4.12 76.18 4.10 75.93 4.10 76.48 4.10 76.59 
4 3.92 68.78 3.96 68.27 3.97 68.40 3.97 68.43 
5 3.71 75.56 3.67 75.33 3.70 76.08 3.69 75.85 
6 3.74 61.85 3.71 61.80 3.73 61.78 3.74 61.76 
6' 3.71  3.75 
 
3.76 
 
3.77  
NeuNAc 
3 2.76 40.35 2.76 40.36 2.76 40.38 2.76 40.47 
3' 1.80  1.83 
 
1.82 
 
1.82  
4 3.68 69.05 3.67 69.30 3.68 69.38 3.69 69.21 
5 3.85 52.36 3.85 52.34 3.85 52.58 3.86 52.50 
6 3.62 73.70 3.63 73.60 3.64 74.05 3.66 73.80 
7 3.65 68.78 3.60 69.05 3.60 69.25 3.31 68.82 
8 3.87 72.59 3.87 72.45 3.88 72.70 3.89 72.65 
9 3.88 63.27 3.86 63.18 3.87 63.54 4.43 63.41 
9' 3.65  3.66 
 
3.66 
 
3.59  
 
 
 
a. NMR experiments were carried out on a Bruker 500 MHz NMR instrument equipped with a TBI cooled probe 
at controlled temperature (± 0.1 K). Data acquisition and processing were performed using TOPSPIN 1.3 and 
3.1 software, respectively. 
b. Gals refers to the residue linked to NeuNAc. 
c. These values were taken from ref 2. 
 
 
As shown in Table 3.1, the 1H and 13C chemical shifts for the signals of the synthesized fragments were in 
excellent agreement with literature NMR data for PSIII and different length fragments2. 
 
 
Figure 3.2. 1H NMR spectra of pentasaccharides 1-3 in comparison to PSIII in Tris buffer pH 7 (D2O, 
500MHz, 298 k) 
 
 
Antibody recognition of linear, branched and Y-shape DP1 by ELISA 
To confirm that the synthesized fragments could be used to study the interactions with PSIII specific mAbs, 
reactivity to the fragments with polyclonal anti-PSIII Abs was confirmed. To this end, linear, branched and 
Y-shape DP1 were first conjugated to CRM197, by treatment with an excess di-N-hydroxysuccinimidyl 
adipate (Figure 3.3)3. The isolated half esters were incubated with the protein in sodium phosphate buffer at 
 
 
pH 7.2. The amount of coupled glycan was proportional to the active ester used in conjugation (Table 3.2). 
Thus the use of 15 equivalents led to incorporation of an average of 3 glycan moieties; when 75 equivalents 
were used the level of carbohydrate incorporation was increased to 24-27 mol/mol of protein. 
After purification by dialysis against sodium phosphate buffer, the glycoconjugates 35-37 were 
characterized by 4-12% sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and  
MALDI TOF MS for the estimation of the carbohydrate/protein molar ratio (Figure 3.4a,b and Table 3.2), 
and by microBCA for the protein content quantification. The degree of carbohydrate incorporation was 
corroborated by quantification of Gal present in the conjugated saccharide through high-performance anion-
exchange chromatography coupled with pulsed amperometric detection (HPAEC-PAD)4.  
 
 
Figure 3.3. Reagents and conditions. a. Di-N-hydroxusuccinimidyl adipate, triethylamine, DMSO; b. 
100mM sodium phosphate pH 7.2. 
 
 
Table 3.2. Attributes of the synthesized glycoconjugates. 
 
Glycoconjugate mol NHS/ 
mol protein 
Protein conc. 
(µg/mL) 
Sacch. conc. 
(µg/mL) 
Average n° of 
saccharide chains  
per protein 
CRM197-DP1 linear 35 15:1 1428 75 3.1 
CRM197-DP1 branched 36a 15:1 1268 64 3.0 
CRM197-DP1 branched 36b 75:1 1035 409 23.0 
CRM197-DP1 Y-shape 37 75:1 1518 700 26.9 
 
 
 
 
Figure 3.4. a) MALDI TOF spectra of synthesized glycoconjugates 35-37; b) SDS-PAGE gel 
electrophoresis of glycoconjugates 35-37 and c) anti-PSIII IgG titers measured by ELISA using 
glycoconjugates 35-37 for coating. Anti-PSIII murine serum was raised with the polysaccharide conjugated 
to a GBS pilus protein; CRM197 and PSIII-CRM197 conjugate were the controls. 
 
Next, the glycoconjugates were used to measure by ELISA specific antibodies present in the anti-PSIII 
murine serum generated by immunization with the polysaccharide conjugated to a GBS pilus protein (Figure 
3.4c). The conjugated compounds of branched and Y-shape DP1 (36-37), presenting a Glc residue β-(1,6) 
linked to GlcNAc, exhibited the highest binding. The recognition of branched DP1 appeared independent 
from its level of incorporation in the obtained glycoconjugates 36a,b. On the opposite, the conjugated linear 
DP1 35 was recognized ~10-fold lower than branched and Y-shape, and only slightly better than the 
 
 
negative control CRM197. As expected, the highest level of anti-PSIII antibodies was detected for the 
positive control PSIII-CRM197 (6-10-fold higher than 36-37). In sum, these data indicated that the presence 
of the branch is a structural relevant motif for the recognition of anti-PSIII antibodies. 
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CHAPTER 4: PREPARATION OF SEMI-SYNTHETIC GBS TYPE III FRAGMENTS 
4.1 Depolymerization and activation of native GBS type III 
For the production of GBS III oligosaccharides, the depolymerization approach reported in the paper of 
Michon of 20061 has been used (Figure 4.1).  
 
 
Figure 4.1. Deaminative cleavage of GBS type III polysaccharide1. 
 
The polysaccharide was partially N-deacetylated in 0.5M NaOH at 70°C. The resulting N-deacetylated 
glucosamine residues in the backbone were then susceptible to nitrosation with nitrous acid and acetic acid 
to form an unstable N-nitrosoamine. The subsequent deaminative cleavage resulted in the production of 
fragments having terminal aldehyde groups. Smaller fragments could be obtained by increasing the time of 
the N-deacetylation reaction. 
N-reacetylation of the fragment was carried out to ensure that all the sialic acid residues were acetylated at 
the end of the depolymerization. 
In order to obtain oligosaccharides with defined composition, an ionic exchange chromatography method 
was developed. Taking advantage of the negative charge of NeuNAc moities, a semi-preparative HPLC with 
a MonoQ column was used. Increasing the sodium chloride concentration in the elution buffer, using a 
staircase gradient, fragments of different length were resolved. As shown in Figure 4.2, each peak of the 
chromatogram corresponded to a subpopulation of saccharides, the shortest fragments of which were eluted 
first. 
 
 
 
 
 
Figure 4.2. Purification of different length oligosaccharides. Mono Q anion-exchange column 
chromatography of depolymerized GBS PS III 
 
Comparison of the 500 MHz 1H NMR spectra of the type III fragments with those of the native GBSIII 
polysaccharide indicated that no structural change had occurred during the chemical processes and, most 
importantly, that terminal sialic acid residues had been preserved during the nitrosation treatment process. 
The length of the purified oligosaccharides was determined by integrating NMR analysis, HPLC-HPAED 
and MALDI TOF MS. The aldheyde proton signal at 5.10 ppm (highlighted in Figure 4.3B), that appears in 
the form of emiacetal in the NMR spectrum of depolymerized GBSIII, can be diagnostic to determine the 
ratio of the terminal 2,5-anhydro-D-mannose residue (blue in Figure 4.3A), generated during the 
depolymerization reaction, compared to the other sugars of the saccharide. In particular, the H-3e (i.e. 
equatorial) position of NeuNAc at 2.75ppm and the H-2 position of Glc at 3.35ppm were preferred for 
oligosaccharide length determination due to their higher resolution in respect to other carbohydrate signals. 
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Figure 4.3. Assessment of PSIII depolymerization. (A) Chemical structure of GBSIII fragments. The 2,5-
anhydri-D-mannose residue obtained during the chemical depolymerization of PSIII is indicated in blue. 
(B) NMR spectra of the full length (in red) and depolymerized (in blue) PS III. 
 
Based on these data, generated fragments were called DP2 (Degree of Polymerization 2), DP3, etc. To 
clarify what it means Degree of Polymerization for the obtained oligosaccharides, it should be highlighted 
that all the fragments obtained using this degradative procedure contained complete RUs of GBSIII, plus an 
appendage consisting of a terminal modified RU. Then, i.e. DP2 (Figure 4.4) contains 1 complete RU 
(highlighted by a red box) and 1 modified RU (the remained five sugars). 
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Figure 4.4. GBSIII DP2 oligosaccharide. (A) Chemical structure of DP2 with the complete repeating unit 
within the red box. (B) Length determination of DP2 by NMR and MALDI-TOF (in negative mode) spectra. 
 
To determine the mass of the first eluted peak and assess the homogeneity of this sample, MALDI-TOF MS 
has been used. Sialic acid is preferentially lost during mass spectrometric investigations2-3. 2,5-
Dihydroxybenzoic acid has been reported to be preferable to α-cyano-4-hydroxycinnamic acid as matrix in 
the analysis of gangliosides, because it minimizes loss of sialic acid4.  Analysis of DP2 (Figure 4.4B) and 
DP3 with this matrix were performed in negative mode, and the OSs length previously obtained by NMR 
was confirmed. The MS spectrum of DP2 is shown in Figure 4.4B: mass peaks correspond to the entire 
saccharide and to a fragment deriving from the loss of one water molecule and one sialic acid residue. 
MS analysis proved that DP2 and DP3 are homogeneous fragments, whereas for longer OSs no proof of 
homogeneity was achieved. Therefore these OSs are indicated as average Degree of Polymerization (avDP). 
Due to the progressive overlapping of the peaks in the chromatography profile, it has been assumed that the 
sample homogeneity decreases as the size of the fragments increases. 
To corroborate the integrity of the obtained DP2 and DP3 observed by NMR analysis, HPAEC-PAD 
analysis was performed with a Dionex ICS3000 equipped with a CarboPac PA1 column. PSIII was used as 
control. The relative ratio of the different sugars composing the polymer was determined (Table 4.1), 
indicating that no significant loss of sialic acid during the depolymerization was produced. Considering that 
 
 
one GlcNAc residue was lost in the entire molecule (the one that was become a 2,5-anhydro-D-mannose 
residue during the reaction), the length of the oligosaccharide was estimated using the formula: 
DP = [X] / ([X]-[GlcNAc]) 
 
where [X] represents the concentration of Glc or half of the concentration of Gal. DPs estimated (Table 4.1) 
by this method were in good agreement with the length assessed through NMR and MS analysis. 
 
 
Table 4.1. HPAEC-PAD quantification of monosaccharide components and relative length estimation. 
Sample GlcNAc µmol/mL  
Glc 
µmol/mL  
Gal 
µmol/mL  
NeuNAc 
µmol/mL  
DP calculated 
by GlcNAc 
DP2 7.71 13.79 30.75 12.91 2.1 
DP3 9.81 14.86 29.46 14.31 3.0 
PSIII 5.86 5.97 12.06 5.83 n.a. 
 
 
 
4.2. Conjugation of GBSIII fragments to CRM197 
The aldehyde group in the resulting 2,5-anhydro-D-mannose residue formed following deamination at the 
reducing end of the polysaccharide fragment represents a useful handle for conjugation and was utilized, 
without further chemical manipulation, for reductive amination with the amines of the CRM197. The 
resulting glycoconjugates contained saccharide chains attached radially to the carrier protein through the end 
terminal residue. This conjugation chemistry was different from that used for the native PSIII where 20% of 
sialic acid residues were chemically activated by NaIO4 oxidation of the glycerol side chain before the 
reductive amination to the carrier, resulting in a cross-linked structure (Figure 4.5). 
 
 
 
 
 
Figure 4.5. Schematic representation of different poly/oligosaccharide-protein chemical couplings5. 
 
Purification of the final glycoconjugates was performed by chromatography on hydroxyapatite, and tuning 
of the phosphate buffer concentration used for elution enabled the separation of the glycoconjugate from the 
unconjugated polysaccharide and protein. Saccharide and protein concentration were obtained by HPAEC-
PAD and BCA analysis respectively. The biochemical characteristics of a series of such type III single-
ended oligosaccharide glycoconjugates varied in the size of their oligosaccharide and in the 
saccharide:protein ratio (average number of saccharide chains per protein or glycosylation degree) as it can 
be seen in Table 4.2. 
 
 
Table 4.2. Biochemical characteristics of GBS type III conjugate vaccines. 
 
Name 
Protein 
concentration 
(µg/mL) 
Sacch. Concentration 
(µg/mL) 
Average n° of saccharide 
chains per protein 
1 CRM-DP2 1122 140 3.5 
2 CRM-DP2 535 160 9.0 
3 CRM-DP3 383 44 2.0 
4 CRM-DP3 484 130 4.5 
5 CRM-DP5 639 159 3.0 
6 CRM-DP5 349 161 5.5 
7 CRM-DP6,5 456 79 1.5 
8 CRM-DP6,5 289 110 3.5 
9 CRM-DP11 531 235 2.3 
 
 
 
The conjugates were controlled before and after the purification step through SDS-PAGE analysis. 
For some glycoconjugates (n°1, 3, 4, 5, 8 in Table 4.2), the glycosylation degree was confirmed by mass 
spectrometry analysis at MALDI-TOF instrument (Figure 4.6). The average molecular weight obtained by 
 
 
MS fits perfectly with the estimated number of saccharide chains per protein. It has been unfeasible to 
analyze by MS glycoconjugates obtained with longer structures. 
 
 
 
 
Figure 4.6. Characterization of the GBS type III conjugate vaccines. MALDI TOF spectra of some 
CRM conjugates 
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5.1. Introduction 
Bacterial cell surface carbohydrates are the interface of multiple host interactions and have been targeted to 
develop highly efficacious glycoconjugate vaccines against severe infections caused by Streptococcus 
pneumoniae, Haemophilus influenzae type b and Neisseria meningitidis1,2. Glycoconjugate vaccines against 
other important pathogens are under clinical or pre-clinical development2.  
Mapping of the epitopes recognised by functional antibodies mediating protection from infection is crucial 
for understanding the mechanism of action of this type of vaccines, as well as for antigen optimization and 
for the development of immunochemical assays. In many cases the antigenic portion responsible for the 
immunological properties of the polysaccharide (PS) and the structural details of the minimal epitope 
targeted by specific functional antibodies are unknown3. 
Minimal epitopes can be composed of short defined glycans comprising 2-3 monosaccharides, as for the β-
(1→2) mannans from Candida albicans cell wall, V. Cholerae O14 or Shighella flexeneri variant Y5 and 
Salmonella6 O-antigens, up to a tetrasaccharide, as for the repeating unit of Streptococcus pneumoniae type 
14 PS (Pn14),7,8 and even six sugar residues, as in the case of Shighella flexneri serotype 2a O-antigen33. In 
contrast, the type III polysaccharide of Streptococcus agalactiae (Group B Streptococcus,‘GBS’) has been 
proposed as a prototype of a unique length-dependent conformational epitope9.  
GBS is an encapsulated Gram-positive β-hemolytic pathogen causing neonatal sepsis and meningitis, 
particularly in infants born to mothers carrying the bacteria10. The GBS capsular PS is constituted by 
multiple repeating units (RU, from about 50 to 300 per polymer) of four to seven monosaccharides shaped to 
form a backbone and one or two side chains. Ten serotypes presenting a unique pattern of glycosidic 
linkages have been identified and their structures elucidated10,11. Three monosaccharides (i.e. β-D-
glucopyranose (β-D-Glcp), β-D-galactopyranose (β-D-Galp), and α-D-N-acetylglucosamine (β-D-GlcpNAc)) 
are present in all the described serotypes, and sialic acid (α-N-acetyl-Neuraminic acid, NeuNAc) is always 
found at the terminus of one chain10,11. Maternal concentrations of antibodies directed to the different GBS 
capsular serotypes inversely correlate with the risk of newborn infection12, suggesting that antibodies able to 
cross the placenta confer serotype-specific infant protection13. PS conjugates of different serotypes elicit 
 
 
antibodies which mediate the GBS serotype specific opsonophagocytic killing in functional assays and 
protection against GBS challenge in neonate mice 14-18. Furthermore, Ia, Ib, III, II and V monovalent 
vaccines, as well as a trivalent combination against types Ia, Ib and III, proved to be safe and immunogenic 
in non-pregnant and pregnant women, and maternal antibodies were transferred to neonates19-21. 
GBS strains belonging to the serotype III (GBSIII) are epidemiologically the most relevant in neonatal 
infections22.  Pioneering immunological studies aimed at elucidating type III specific antigenic determinants 
indicated the presence of the terminal NeuNAc residue as essential for the elicitation of protective 
antibodies23. Subsequent studies revealed that sera from rabbits immunized with GBSIII bacteria and from 
humans vaccinated with PSIII conjugates contained two types of anti-carbohydrate antibodies, i.e. a major 
population recognizing the native polysaccharide but not its incomplete core antigen derivative lacking sialic 
acid (corresponding to the Pneumococcus PS Pn14), plus a variable population reacting with both the native 
PSIII and the core antigen24,25.  Remarkably, both types of human PSIII-induced antibodies were shown to 
mediate GBSIII opsonophagocytic killing (OPK), while antibodies elicited by Pn14 (desialylated PSIII) did 
not recognize GBSIII bacteria and therefore did not mediate GBS killing21. 
Subsequent 13C NMR spectroscopy studies highlighted ring-linkage signal displacements in the core versus 
the native PS, suggesting that NeuNAc residues exert a specific conformations over the native 
polysaccharide24,26. Molecular dynamics simulations confirmed a more flexible and disordered structure for 
desialylated PSIII, and suggested that native PSIII could form extended helical structures whose turn was 
made by more than four RUs27-29.  PSIII fragments smaller than four RUs appeared as weak inhibitors of the 
binding of native PSIII to its specific antibodies, and failed to elicit an efficient immune response following 
conjugation30. 
Based on the above observations, it was concluded that the native PSIII forms a sialic acid-dependent 
conformational epitope that is essential for the elicitation and recognition of functional antibodies; the 
length dependency of this conformational epitope was ascribed to its localization on extended helices within 
a random coil structure30. According to the proposed model, the side chain NeuNAc moiety would exert a 
remote control over immunological determinants of the PS backbone, without being a direct part of the 
epitope31.   
A structural glycobiology approach of bacterial oligosaccharides in complex with functional monoclonal 
antibodies (mAbs) able to protect against the target pathogen, could represent the most direct methodology 
to gain information on PS immunological determinants at atomic level. However, due to the high polarity of 
the hydroxyl groups and flexibility of the carbohydrate structures32, crystallization of carbohydrate-protein 
complexes is a challenging task. To date only a very limited number of carbohydrate antigen-Fab complexes 
have been resolved by X-ray crystallography4-6,33. As alternative, a combination of different techniques 
(NMR, Surface Plasmon Resonance (SPR), Isothermal Titration Calorimetry (ITC), glycoarray, competitive 
ELISA) is typically used to gain insights on carbohydrate-protein interactions and to map the binding 
regions3,34-36. 
 
 
In the present study we used STD-NMR and X-ray crystallography to investigate the interaction of GBSIII 
oligosaccharides obtained by synthetic and depolymerization procedures, with a protective monoclonal 
antibody.  
 
5.2. Results 
5.2.1. Selection and immunochemical characterization of a functional anti-PSIII rabbit monoclonal 
antibody  
To investigate the binding of GBS PSIII to functional antibodies at atomic level and further decipher the role 
of the NeuNAc moiety, we first generated a rabbit anti-PSIII monoclonal antibody (mAb) capable of 
mediating GBS opsonophagocytic killing. Similarly to a previous report20, rabbits immunized with native 
PSIII conjugated to genetically detoxified Diphteria Toxin (CRM197) developed two types of antibodies 
differing in their capacity to bind the PSIII desialylated core antigen in addition to the native polysaccharide. 
Indeed, inhibition ELISA experiments showed that binding of IgG from rabbit sera to immobilized PSIII 
unconjugated (Figure 5.1) or conjugated to HSA37 (Figure 5.2a) could be partially blocked by pre-incubation 
with soluble Pn14 or desialylated PSIII. Pn14 also partially inhibited antibody-mediated GBSIII OPK 
(Figure 5.2b), confirming functional activity of both types of NeuNAc dependent and independent rabbit 
antibodies. Similar results were described previously in the case of human responses to GBSIII21. 
 
 
Figure 5.1. Antibody specificity toward PSIII. Inhibition ELISA binding of rabbit sera to immobilized 
PSIII unconjugated by pre-incubation with PSIII and Pn14. 
 
 
 
Figure 5.2. Antibody specificity toward PSIII. Inhibition experiments with PSIII and Pn14 of rabbit anti- 
PSIII pAb and anti-PSIII mAb in (a) ELISA binding immobilized PSIII conjugated to HSA and (b) OPK. 
 
An IgG1 mAb was selected by hybridoma cell line technology (NVS-1-19-5), for which functional activity 
was ascertained by OPKA (OPK titer: 1.03µg/mL). Complete inhibition by native PSIII and absence of 
inhibition by Pn14 in ELISA and OPKA experiments (Figure 5.2a and 5.2b) confirmed that the epitope 
recognized by this mAb was sialic acid-dependent. A Fab fragment of mAb NVS-1-19-5 was then prepared 
by papain proteolytic cleavage, and high affinity binding towards the GBS PSIII was measured by SPR (KD 
estimated with the Fab 6×10-8 M).  
The NeuNAc-Gal covalent link in the lateral chain of the PSIII repeating unit is the more chemically labile 
glycosidic bond within the polysaccharide, and complete loss of NeuNAc residues or reduction of their 
carboxylic groups results in polysaccharide structures incapable of inducing functional antibodies24. To 
investigate the potential of the obtained mAb for probing the integrity of the PSIII antigen, we subjected 
a 
b 
 
 
PSIII-CRM197 to mild acid hydrolysis for different incubation times and obtained conjugates with decreasing 
sialylation levels of 100, 60-70, 20-30 and <5%, as estimated by NMR analysis (Figure 5.3 and Table 5.1).  
 
 
 
Figure 5.3. Estimation of desialylation level. 1H NMR spectra of PSIII-CRM197 at different reaction times 
(Table 5.1). 
 
 
Table 5.1. Percentage of bound sialic acid content estimated by 1H NMR.  
Reaction Time (h) 0 6 24 72 
% NeuNAc
in chain
 
100 60-70 20-30 <5.0 
 
 
 
 
 
 
 
 
 
 
 
 
The resulting glycoconjugates were characterized for their structural integrity and saccharide/protein content 
(Figure 5.4 and Table 5.2).  
 
Figure 5.4. Gel electrophoresis of CRM197 PSIII conjugates. SDS-Page 3-8% Tris acetate gel of 
desialylated PSIII-CRM197 at different reaction times (Table 5.1). 
 
 
Table 5.2. Saccharide and protein content in PSIII-CRM197 conjugates selected for immunization. 
Sample  
(% bound NeuNAc)  
Protein  
(µg/mL)  
Sacch. (Gal-based)  
(µg/mL)  
Sacch./Prot. 
(w/w)  
PSIII-CRM197 100% 695.7 837.7 1.2 
PSIII-CRM197 60-70% 884.6 930.2 1.1 
PSIII-CRM197 20-30% 785.5 768.1 1.0 
PSIII-CRM197 <5.0% 872.0 703.8 0.8 
 
 
ELISA experiments using immobilized native PSIII and, as competitor, soluble native or partially 
desialylated PSIII-CRM197 showed decreasing binding of the mAb to conjugates with increasing 
desialylation levels (Figure 5.5a). The capital role of the NeuNAc in elicitation of functional antibodies was 
confirmed by immunizing female mice with three doses of the different glycoconjugates, followed by sera 
analysis by ELISA for quantification of anti-PSIII and anti-Pn14 antibodies, and by OPKA to assess 
antibody functional activity. Lower levels of sialylation resulted in decreased recognition of HSA-
conjugated native PSIII (Figure 5.5b-d), higher recognition of Pn14, and decreasing in vitro killing of GBS 
bacteria.  
SDS-Page 3-8% 
 
1. MW 
2. CRM197 
3. CRM197-III Ref. Vaccine 
4. CRM197-III 100% 
5. CRM197-III 70-80% 
6. CRM197-III 20-30% 
7. CRM197-III <5% 
 
 
 
 
Figure 5.5. Effect of desialylation on the immunogenicity of PSIII conjugates. (a) anti-GBS PSIII IgG 
titers (EU/ml) for groups of eight mice vaccinated with i.p. injection of glycoconjugate with different level 
of sialic acid. Sera were analyzed after the third immunization. Alum was used as negative control. Mean 
(red columns) and standard deviations (black bars) are reported; (b) OPK titers measured testing the sera at 
different serial dilutions. Reported OPK titers correspond to the serum dilution inducing 50% bacteria 
killing, as described in literature; (c) anti-Pn14 IgG titers (EU) calculated as the dilution giving OD of 1.0 in 
ELISA plates coated with Pn14-HAS; (d) inhibition percentage of mAb NVS-1-19-5 binding to ELISA 
plates coated with PSIII conjugated to HSA using, as competitors, glycoconjugates containing different 
percentages of sialic acid. 
 
 
 
 
 
 
5.2.2. Selection of the glycan fragments for structural studies 
Antibodies elicited in mice by PSIII have been shown to bind oligosaccharide fragments in a length 
dependent manner30,31. Using a competitive ELISA assay, it was demonstrated that at least 2 unmodified 
repeating units (2 RU) were necessary for suboptimal binding to a GBSIII-specific mouse mAb, while 
inhibition with 3 to 7 RUs moderately increased and became much higher above this number of RU27.  SPR 
experiments using a Fab fragment of the same mAb confirmed that the affinity (KD) was comparable 
between 2 and 6-7 RUs, it increased by 3-fold from 6-7 RU to 20 RUs, and remained constant beyond this 
point30.  
To investigate more in detail the epitope recognized by the selected functional mAb, we generated a set of 
PSIII oligosaccharide fragments by partial de-N-acetylation followed by nitrosation38.  Improvements in the 
purification described by Paoletti et al.39, by using an anionic exchange HPLC in place of a size exclusion 
chromatography, allowed the isolation of fragments with a degree of polymerization (DP) in the range of 2-
15 with a defined composition (Figure 4.2). These fragments were composed of a modified RU and a 
variable number of unmodified RUs (Figure 5.6).  
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Figure 5.6. Chemical structure of GBS PSIII and glycan probes used in this study. The red highlighted 
GlcNAc residue is used as reference monosaccharide to outline the three possible sugar sequences related to 
PSIII repeating unit. The 2,5-anhydri-D-mannose residue obtained during the chemical depolymerization of 
PSIII is indicated in blue. 
 
 
Length dependent recognition of the different fragments was firstly confirmed by competitive ELISA with 
the selected rabbit mAb NVS-1-19-5 (Figure 5.7)30.  
 
 
 
Figure 5.7. Specific length dependent recognition of rabbit mAb. Inhibition curves derived from ELISA 
inhibition data on the binding PSIII-HSA to rabbit mAb NVS-1-19-5 using PSIII and its fragments as 
inhibitors. 
 
As expected, this difference slightly increased from DP2 to 11 up to 1-log and became 5-log higher when 
PSIII was used as inhibitor26. To exclude the effect of the bivalent interaction of mAb on the avidity, we 
performed a competitive SPR assay where different oligosaccharide fragments (DP1-13 range) were tested 
as competitors for the binding of soluble Fab fragment to PSIII conjugated to Human Serum Albumin (HSA) 
immobilized on the chip. Two major populations of inhibitors, DP≥2 and DP<2, were differentiated (Figure 
5.8 and Table 5.3).  
 
 
 
 
Figure 5.8. Competitive SPR of the binding between the rabbit Fab and PSIII. Different length 
fragments were used as inhibitors. PSIII and the Pn14 PS (i.e. PSIII fully desialylated) were the positive and 
negative control, respectively. 
 
 
Table 5.3. IC50 for different length glycans 
Glycan IC50 (µg/ml) 
DP1 linear -3 3119.00 
DP1 Y-shape -2 1233.00 
DP1 branched -1 1118.00 
DP2 14.29 
DP3 2.59 
avDP4.5 1.23 
avDP8.5 0.64 
avDP13.5 0.46 
PSIII 0.17 
Pn14 nd 
 
 
DP≥2 oligosaccharides showed asymptotically increasing affinity up to the native PSIII, with only 2-log 
difference between native PSIII and DP2.  Concerning the single RUs, a 2-log difference was observed 
between DP2 and the synthetic branched and Y-shape (1 and 2) DP1 having a β-Glc-(1→6)-β-GlcNAc 
branching; conversely, a very weak inhibition was detected with the linear structure (3), suggesting that the 
arrangement of sugars in the RU impacts Ab recognition and the ramification point is relevant for binding.  
The binding affinities of the native PSIII and the DP2 fragment to the rabbit Fab were also compared by 
conjugating the two polysaccharide structures to CRM197 and immobilizing them on a SPR chip. The two 
binding constants determined according to a 1:1 fitting model differed by less than 10 fold (Figure 5.9 and 
Table 5.4)40,41.  
 
 
 
 
Figure 5.9. Binding kinetics and affinities of PSIII and DP2. Fitting to a 1:1 interaction model of Fab 
NVS-1-19-5 binding to the PSIII-CRM or DP2-CRM surfaces. Both surface density were 250 resonance 
units. 
 
 
Table 5.4. Kinetic and affinity constants for Fab NVS-1-19-5 binding to PSIII or DP2 CRM-
conjugates. 
 
 
Overall, this preliminary analysis confirmed a length-dependent affinity of anti-PSIII GBS antibody but also 
indicated that DP2 contains the PSIII portion necessary for high affinity antibody binding and could be used 
for further structural analysis. 
 
5.2.3. Identification of the PSIII antigenic determinant by STD NMR  
To map the interactions of  PSIII fragments with the protective mAb, Saturation Transfer Difference NMR 
(STD NMR) studies were undertaken42,43.   
 
 
 
 
Figure 5.10. GBS PSIII epitope mapping. (a) Protons interacting with the mAb identified by STD NMR 
and X-ray crystallography; (b) STDD and (c) related 1H NMR spectra of the desialylated tetrasaccharide (β-
Gal-(1→4)-β-GlcNAc-(1→3)-β-Gal-(1→4)-α/β-Glc in green), the linear 3 (blue) and branched 1  (red) 
repeating units, and the DP2 fragment (black). Proton positions receiving saturation after irradiation of the 
protein are indicated. ‡ indicates the CH2 signal of the Tris buffer; * refers to signals related to the protein. 
 
 
 
 
STDD NMR spectra were derived by subtracting the STD NMR spectrum of the glycan in the bound state 
with the mAb (ligand/protein 15-50:1 molar ratio) to the reference spectrum in the unbound state. The DP3 
STDD spectrum was super-imposable to the one obtained for the DP2-mAb complex (Figure 5.11), 
highlighting that the mAb was recognizing identical regions in the two fragments. Due to their higher 
affinity constants and larger size, experiments carried out on longer fragments (5.5 and 8 RUs) resulted in 
lower signal intensities that did not allow unequivocal detection of saturation transfer effects.  
 
 
Figure 5.11. Comparison of DP2 and DP3 mapping. 1H (bottom) and STDD-NMR (top) comparison of 
DP2-DP3–mAb complexes (Black lines DP3, red lies DP2).* labeled resonances match to mAb 
signals/impurities. 
 
Notably, most of the 1H NMR resonances that could unequivocally be assigned to the DP2-mAb complex 
were related to the α-NeuNAc-(2→3)-β-GalB-(1→4) residues (Figure 5.10a), indicating a direct involvement 
of this branch, in addition to the Glc and Gal residues of the backbone. In the DP2 oligosaccharide it was not 
possible to differentiate the NAc group of NeuNAc and GlcNAc. To better discriminate the exact positions 
engaged in antibody interaction, the synthesized DP1 was complexed with the mAb and analyzed by STDD 
NMR. As shown in Figure 5.10b-c, well recognizable resonances of the branched repeating unit 1 were 
recovered in the STDD spectrum with medium-high saturation intensity (>50%). The highest transfer of 
saturation was observed for the H-5 (3.85 ppm), H-4 (3.70 ppm), H-3 (2.76 and 1.82 ppm for equatorial and 
axial, respectively) and H-6 (3.65 ppm) of NeuNAc (Figure 5.10b), confirming that NeuNAc is the major 
anchoring site for mAb interaction. A similar pattern of signals related to the NeuNAc was obtained with 
linear and Y-shape DP1 (Figure 5.12). Further, the involvement of the NeuNAc N-acetyl group, not clearly 
distinguishable from the one of GlcNAc residue in the DP2, was unveiled in the synthetic probes at 2.0 ppm. 
 
 
When the desialylated tetrasaccharide [β-Gal-(1→4)-β-GlcNAc-(1→3)-β-Gal-(1→4)-α/β-Glc] was analyzed 
in presence of the mAb, no transfer of saturation was observed. 
 
 
 
Figure 5.12. Comparison of synthetic DP1 glycans mapping. Comparison of mAb-DP1 STDD NMR 
spectra (top) and of 1H NMR spectra (bottom) of DP1 branched (black lines), DP1 linear (red lines) and DP1 
Y-shape (blue lines).* labeled resonances match to mAb signals/impurities, while assignments are referred 
to NeuNAc resonances. 
 
 
A high STD signal was observed for the Glc H-2 position at 3.37 ppm in the DP2, the branched and Y-shape 
DP1 repeating units (Figure 5.12) in complex with the mAb, whereas no recovery was seen for this position 
in the linear repeating unit 3 where the Glc moiety is located far from the NeuNAc (Figure 5.10b-c). 
Previous conformational studies have revealed that the orientation of Glc backbone residue in the backbone 
was affected by removal of sialic acid, indicating the spatial proximity of the two residues20. The transfer of 
saturation to the H-2 of Glc indicated that the mAb binding of this residue is determined by its intrinsic 
location in the sugar sequence29.  
Owing to the better resolution of the STD NMR spectra of the synthetic glycans, the saturation transfer was 
more precisely quantified for some of the protons involved in binding. Experiments at increasing saturation 
times from 0.5 up to 5.0 sec were performed to avoid possible bias in the calculation of STD effects due to 
different proton longitudinal relaxation times (T1), or intramolecular spin diffusion within the bound state 
(Figure 5.13). In the branched synthetic glycan 1 an STD effect of 100, 96 and 70% was measured for H-5, 
H-3eq signals of NeuNAc and H-2 of Glc, respectively.  
 
 
 
Figure 5.13. STD amplification factor as a function of saturation time. Data were fitted to the 
monoexponential equation STD = STDmax [1 − exp(−ksatt)]. 
 
Taken together, these results unambiguously showed that the side chain NeuNAc and Gal residues, together 
with the Gal and Glc backbone sugars of the RU, directly interact with the mAb. 
 
5.2.4. Structural studies of the PSIII-Fab complex by X-ray crystallography 
To further elucidate the basis for the interaction of PSIII and the mAb at atomic level, we used X-ray 
crystallography to determine the three-dimensional structure of DP2 in complex with the NVS-1-19-5 Fab 
fragment. Crystals of this complex, belonging to space group C2221 and containing two copies of a 1:1 DP2-
Fab complex in the asymmetric unit (ASU), diffracted up to a resolution of 2.7 Å. The structure was solved 
by molecular replacement, using as template input model the coordinates of a rabbit Fab (PDB 4JO1) with 
which Fab NVS-1-19-5 shares 79% sequence identity. Excellent electron densities allowed the modeling of 
residues Gln20-Ser245 of the heavy (H) chain and Val24-Cys238 of the light (L) chain of the Fab, as well as 
the full DP2 oligosaccharide. The final coordinates of the complex were refined with Rwork/Rfree values of 
21/27% (Table 5.5). Structural superimposition of the two copies of the Fab present in the ASU resulted in 
very low carbon alpha root mean square deviation (Cα rmsd) values (~0.5 Ǻ; the two structures are 
essentially identical), and their bound DP2 conformations were also highly similar; therefore, one copy will 
be used for description of the structure.  
 
 
Table 5.5.  Data collection and refinement statistics. 
 GBS DP2-Fab NVS-1-19-5 
Data collection  
Wavelength (Å) 0.966 
Resolution range (Å) 46.43  - 2.74 (2.838  - 2.74) 
Space group C 2 2 21 
Unit cell a, b, c (Å) 135.34 142.23 144.73 
Total reflections 164737 (14300) 
Unique reflections 36702 (3512) 
Multiplicity 4.5 (4.1) 
Completeness (%) 99 (96) 
Mean I/sigma(I) 12.12 (1.45) 
Wilson B-factor (Å2) 67.72 
Rmerge 0.08093 (0.7761) 
Rmeas 0.09201 (0.8913) 
Rpim 0.04278 (0.428) 
CC1/2 0.998 (0.649) 
CC* 0.999 (0.887) 
 
Refinement 
 
Reflections used in refinement 36701 (2864) 
Reflections used for R-free 1834 (130) 
Rwork 0.2008  
Rfree 0.2503  
Number of non-hydrogen atoms 7064 
  macromolecules 6479 
  ligands 316 
  solvent 269 
Protein residues 879 
RMS(bonds) (Å) 0.01 
RMS(angles) (°) 1.29 
Ramachandran favored (%) 92.3 
Ramachandran outliers (%) 1.1 
Rotamer outliers (%) 9.6 
Clashscore 5.92 
Average B-factor (Å2) 74.21 
  macromolecules 73.51 
  ligands 98.29 
  solvent 62.97 
PDB ID 5M63 
Statistics for the highest-resolution shell are shown in parentheses. 
Rwork = Σ||F(obs)|- |F(calc)||/ Σ|F(obs)| 
Rfree = Rwork but calculated for 5 % of the total reflections, chosen at random and omitted from refinement. 
 
 
 
 
 
 
 
The Fab fragment binds the glycan with an extended interface (577 Å2) formed by two adjacent pockets that 
are located between the light and the heavy chain of the Fab (Figure 5.14a-b). Most of the observed contacts 
are related to a single PS repeating unit, whereas the sugar residues of the consecutive RU depart from the 
binding pockets, with the exception of GlcNAc-A'' which is directly bound to the Fab. The larger pocket 
hosts the NeuNAc of the RU branch that interacts with multiple hydrophilic residues of the CDRs from both 
the heavy and the light chains. Specifically, Arg56 of the light chain forms a hydrogen bond with the N-
acetyl group of NeuNAc-C' and His127 interacts with its O-4. Additional weaker interactions of NeuNAc-C' 
occur through water molecule bridges, as observed for the carboxylic group of the sugar and Asn 74 of the H 
chain, and the CH-π interaction between Tyr52 of the L chain and the sialic NAc methyl group (Figure 
5.14c). 
The GlcNAc-A'' residue appears involved in the binding to the smaller anchoring pocket of the Fab through 
at least two hydrogen bonds formed by the L chain Arg56 and Lys74 with the NAc group and the O-3 
position of the sugar, respectively. The NAc group is stabilized by a CH-π interaction with Tyr126 and by 
water molecules trapped in the cavity by a network of H-bonds. Interestingly, the guanidine group of Arg56 
is located within H-bond distance from the NAc carbonyl groups of both NeuNAc-C' and GlcNAc-A'', 
whose methyl groups are at the same time favorably oriented to make CH-π interactions with the phenyl 
rings of Tyr52 of the L chain and Tyr126 of the H chain, respectively. This arrangement allows for a 
peculiar symmetric network of interactions involving the NeuNAc of one RU and the GlcNAc of a 
consecutive unit (Figure 5.14d). Complete de-N-acetylation of these residues resulted in loss of Fab 
recognition as demonstrated by Competitive SPR (Figure 5.15). 
Inspection of the glycan structure revealed how Gal-E', though positioned outside of the two binding 
pockets, interacts with side chain atoms of Asn53 of the L chain and of Tyr126 of the H chain. The side 
chain of Tyr126 seems also favorably positioned to engage H-bond mediated interactions with the O-3 
position of Glc-D'. Interestingly, GlcNAc-A' that was modified into 2,5-anhydro-D-mannose during the 
depolymerization reaction appears to be far from the anchoring pocket, hence its chemical manipulation 
during depolymerization did not interfere with the binding to the Fab. 
The DP2-Fab complex crystal structure also reveals how NeuNAc-C' and Glc-D' appear to be in close 
contact, with a calculated distance between the O-9 atom of NeuNAc and the O-6 of Glc of 2.8Å. This 
suggests that hydrogen bonds between these two positions might be further stabilized upon binding to the 
Fab (Figure 5.14c). In summary, our structure clearly showed that the side chain NeuNAc and the backbone 
Gal and Glc of the first RU, as well as the backbone GlcNAc of the consecutive RU interact with multiple 
hydrophilic residues of the CDRs from both the heavy and the light chain while the NeuNAc glycerol 
moiety is involved in internal interactions rather than in direct binding to the Fab. 
 
 
 
Figure 5.14. Crystal structure of DP2 bound to Fab NVS-1-19-5. (A-left) The Fab is depicted with 
surfaces, while DP2 with sticks. Fab residues involved in direct binding with DP2 (the paratope) are colored 
in yellow on the left. Binding pockets are shown with arrows and labelled. (A-right) Surface electrostatic 
 
 
distribution of the Fab; (b) Fab-DP2 complex with light chain in light grey and heavy chain in dark grey; (c) 
Direct interactions between and the Fab. Carbon atoms of the DP2 backbone are colored in yellow, and 
those belonging to the branches are in green, while carbon atoms of the Fab are colored in light and dark 
gray for the L and H chain, respectively. Nitrogen and oxygen atoms are colored in blue and red, 
respectively, and water molecules are shown as red spheres. (d) Zoom into the interactions between the Fab 
and the NAc groups of NeuNAc-C' and GlcNAc-A'', showing hydrogen bonds between the NAc carbonyl 
moieties and the guanidinium group of Arg56, and the CH-π interactions between the NAc methyl groups 
and the phenol of Tyr52 of the L chain  and Tyr126 of the H chain. Hydrogen bonds in panels c+d are 
depicted with black dashes. 
 
 
Figure 5.15. mAb recognition of de-N-acetylated PSIII. Competitive SPR of the binding between the 
rabbit Fab NVS-1-19-5 and PSIII conjugated to HSA, using PSIII at different percentage of de-N-
acetylation. PSIII was the positive control. 
 
 
5.3. Discussion 
The definition and characterization at atomic level of polysaccharide epitopes targeted by protective 
antibodies is relevant for the design, description and even registration of glycoconjugate vaccines. 
In this study we aimed to characterize the antigenic determinant of the capsular polysaccharide from the 
clinically relevant serotype III of GBS, a pathogen for which a vaccine is under evaluation in clinical trials. 
A GBS vaccine is expected to improve the overall coverage of protection against Early Onset neonatal 
disease, currently only partially achieved with IAP prophylaxis, and to fill an important medical gap by 
targeting prevention of late-onset GBS disease (LOD), stillbirths, miscarriages and prematurity.   
The GBS polysaccharide III has been considered as a conformational epitope prototype, based on NMR 
simulation studies indicating the formation of one of several potential helical structures27,29, where sialylated 
 
 
side chains are arranged on the exterior surface of the helix. The PSIII helix is thought to be stabilized by the 
presence of a) specific interactions between the side chain sialic acid and the backbone glucosyl and 
galactosyl residues, influencing the orientation of the side chain and stabilizing the conformation of the 
backbone, and b) a carbohydrate chain length of at least 4 pentasaccharide RUs which introduces a 
conformational epitope equivalent to one present in the native PSIII. Shorter carbohydrate chains are 
subjected to conformational changes and in absence of specific interactions the overall helical structure 
collapses27. The need for a helical epitope for antibody recognition was hypothesised also considering that, 
similarly to other polysaccharides including serogroup B Neisseria meningitidis CPS, GBS PSIII showed a 
length dependent binding of specific monoclonal IgGs30. Zou et al. observed that KD measured by SPR for 
monovalent binding remained virtually constant from 2 to 7 RUs which demonstrated that the epitope 
optimization was occurring from 2 to 7 RUs, while beyond 20 RUs this phenomenon would overlap with the 
multivalent exposition of stabilized epitopes. Moreover, Johnson et al. showed by STD NMR experiments 
that  NeuNAc was not involved in the binding to a monoclonal IgM44. 
Further molecular dynamics (MD) simulation confirmed the role of sialic acid in maintaining the helical 
structure and how preponderant is this conformation of the polysaccharide prior to antibody binding27. 
However a question was not addressed: Is the helical conformation pivotal for binding of PSIII to 
antibodies?  
We undertook a structural glycobiology approach to deeply investigate this intriguing feature, and further 
define the relevance of the NeuNAc residue in PSIII immunogenicity. Preliminary results obtained with 
mice immunized with PSIII-CRM197 conjugates with different levels of sialylation confirmed that the 
presence of NeuNAc is determinant to generate protective antibodies and that native PSIII GBS elicits two 
types of antibodies differing in sialic acid dependency24,25. 
A rabbit functional monoclonal IgG belonging to the major PSIII-specific sialic-acid dependent population 
was selected for structural analysis. This mAb also provides a useful analytical tool for discriminating 
sialylated (native) and partially desialylated PSIII GBS during the isolation, purification and conjugation 
steps for vaccine antigen production.  
A set of oligosaccharides of different length was prepared by semisynthetic and synthetic methods. By using 
these fragments we first confirmed by competitive ELISA the length dependency of mAb binding to GBS 
PSIII oligosaccharides30. The difference in affinity among the fragments remarkably decreased from 5 to 2 
log fold, when bivalent binding of the mAb was avoided by the use of a Fab fragment. The increase of 
affinity with growing saccharide lengths was progressive and no major difference in this trend was observed 
above 4-5 RUs. In addition, SPR binding affinity of the Fab to DP2-CRM and native PSIII-CRM conjugates 
varied within a narrow range (10-100 nM). Based on the above data, we assumed that the Fab binding to 
PSIII would presumably involve no more than 2 RUs, and the observed rise in affinity with fragments of 
increasing length could be justified by multivalency effects rather than the need for a helical conformation.  
 
 
To demonstrate this hypothesis, we performed STD NMR and X-ray crystallography experiments using the 
Fab and DP≤2 RU. The information obtained by these two techniques was in good agreement, and is 
summarized in Figure 5.10a. STD NMR unequivocally showed that NeuNAc in the branch and Gal and Glc 
residues in the backbone of the RU are the structural motifs that are recognized by the antibody. 
Furthermore, the branched DP1-1 contains most of the structural elements for mAb interaction. Ring protons 
of NeuNAc were shown not to receive STD effect in a carbohydrate-IgM complex analyzed by STD NMR, 
although saturation was transferred to an N-propionyl group used in replacement of the NAc44. One possible 
explanation of the difference with our results could be that the isolated protective IgM was directed to the 
second type of antibodies cross-reactive with Pn14 present in anti-PSIII sera. 
X-ray crystallography data confirmed the interactions for NeuNAc-C', Glc-D' and Gal-E' residues. 
Additionally, it showed that the GlcNAc-A' residue is outside the Fab binding pocket and not involved in the 
recognition, while the GlcNAc-A'' of a proximal RU contributes to the stabilization of the interaction with 
the Fab. This result could explain the difference in binding affinity between DP1 and DP2 observed by 
competitive SPR. With the exception of GlcNAc-A'', the consecutive repeating unit is exposed externally to 
the binding area, therefore longer structures would likely not be accommodated by the Fab. STD NMR 
revealed an interaction involving the Gal-B' of the branch, which did not appear in the crystal structure. This 
could be ascribed to higher flexibility of the α-NeuAc-(2→3)-β-GalB-(1→4) branch in the liquid solution 
compared to crystallography which facilitates transfer of saturation to the Gal residue.  
Intramolecular interactions between NeuNAc and Glc have been long debated, as oxidation of the glycerol 
side chain is typically used in the preparation of glycoconjugate vaccines. The proximity of these residues 
has been suggested by a chemical shift of Glc related signals in NMR spectra after modification of H8-H9 
positions24,29. Torsion angles distribution for NeuAc and the interactions of this residue with Glc have been 
used as paramaters to build the helical model39. On the other hand, in silico studies suggested no hydrogen 
bonding formation between NeuNAc and Glc27. STD NMR and X-ray data confirmed the structural 
proximity of NeuAc and Glc, facing each other in the Fab complex independently from the presentation in a 
helical structure. The glycerol group appeared engaged in H-bond formation with Glc. Acetylation of 
positions C-7, -8 and -9 was found in various clinical isolates including PSIII expressing strains45, although 
this feature was demonstrated not to be relevant to elicit functional antibodies46. Furthermore, moderate 
oxidation of the C-9 position is known to be well tolerated for PSIII conjugation to carrier protein16. 
Therefore the H-bond interaction of the glycerol moiety with Glc might not have an impact on the 
immunogenicity. 
In summary, the glycan epitope for GBS PSIII is composed of five non-consecutive residues highlighted by 
the trapezoidal area (Figure 5.10a), and it would involve an additional GlcNAc residue of the vicinal 
repeating unit, as demonstrated by exploring the branched glycan 1 containing the additional a GlcNAc-A'' 
residue. It is worth of note that, the β-Glc-(1→6)-β-GlcNAc linkage creates a ramification in the 
carbohydrate structure that is discriminant for mAb affinity and recognition.  
 
 
This creates a spatially defined but discontinuous motif which involves sugars from the branch and the 
backbone of the polysaccharide, and that can be defined as a conformational epitope. Indeed, this type of 
epitope is a distinctive motif compared to the linear epitopes involving 2-3 consecutive residues that were so 
far mapped by structural studies for V. Cholerae O14, Shighella flexeneri variant Y and Salmonella O-
antigens5,6, while it seems more similar to Shighella flexneri serotype 2a O-antigen33,
 
where an epitope 
involving 6 out of 10 monosaccharides from 2 RUs is recognized by Fab. Importantly, the described PSIII 
epitope is totally independent from the existence of a helical structure whereas it appears generated by the 
presence of branches in the polysaccharide.  
Carbohydrates present a higher level of complexity compared to other classes on natural biopolymers such 
as polypeptides or polynucleotides, because of the presence of α- or β-glyocosidic bonds and the occurrence 
of connections at different positions of the ring which create ramifications. These unique features would 
result into spatial motifs that would be relevant for antibody recognition and specificity even in the presence 
of a limited number of sugar residues, as it has been demonstrated here for GBS PSIII. In this manner, the 
need for the human immune system to recognize GBS PS by means of their length dependent helical 
structures in order to avoid recognition of self-antigens containing sialic acid would need to be 
reconsidered31.  
The finding that the PSIII epitope is defined within a limited number of sugars confirms our initial 
hypothesis that differences in affinity to the Fab with increasing fragment lengths could be explained based 
on the statistical rebinding of the Fab to consecutive defined epitopes as displayed on the SPR chip. The 
rabbit anti-PSIII mAb studied here provides a useful analytical tool for discriminating sialylated (native 
PSIII) and desialylated (equivalent to Pn14) PSIII GBS.  
New approaches for the preparation of glycoconjugate vaccines which eliminate the fermentation of 
pathogens and deliver more defined products are emerging. These include the use of synthetically made 
oligosaccharide47, the in vivo E. coli expression of glycoproteins48 or in vitro polysaccharide production49. 
The existence of helical conformational epitopes which would imply the necessity of using long 
polysaccharide antigen has been considered a challenge to apply these technologies to certain pathogens.  
The elucidation and understanding of the structural bases for the immune recognition of carbohydrate 
epitopes reported here paves the way to the design of glycoconjugate vaccines, as well as contributes to 
accelerating the development of modern vaccines based on chemoenzymatic or bioengineering methods. 
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CHAPTER 6 
 
Determining the minimal epitope of GBS PSIII and the effect of its multivalent presentation  
onto the carrier protein on the immunogenicity 
 
 
6.1. Introduction 
Since the beginning of XIX century, vaccines have become a hugely important and successful 
countermeasure to the threat of infectious disease1. Vaccines provide protection by inducing humoral and/or 
cellular immunity to disease-causing pathogens. The dense surface distribution of often unique glycan 
structures on diverse pathogens and on malignant cells makes carbohydrates attractive vaccine targets2. The 
surface of bacterial pathogens is covered with a dense array of polysaccharide that is a unique feature of not 
only the particular species, but also the strain of bacteria considered. Carbohydrate-specific antibodies are 
predominantly responsible for protection against bacteria with either a capsule or lipopolysaccharide on 
their surfaces. People lacking these antibodies, for example the elderly and neonates, are at high risk of 
developing infections. With the increasing prevalence of antibiotic-resistant bacterial strains, the proven 
track record of capsular polysaccharide-based vaccines has encouraged the development of these types of 
vaccines against a broader range of pathogens. For many bacterial infections, glycoconjugate vaccines have 
been made based on fragments of their capsular polysaccharides, for example Streptococcus pneumoniae, 
Neisseria meningitides and Haemophilus influenzae3. 
Administration of capsular polysaccharides (PS) has been part of routine vaccinations against a variety of 
pathogenic bacteria for many years, but it is effective only in the adult population4. This major limitation of 
plain polysaccharide vaccines can be overcome by chemical conjugation to a carrier protein as T-cell helper, 
such as the chemically detoxified diphtheria and tetanus toxoid (DT and TT, respectively) or the genetically 
detoxified diphtheria toxin (CRM197). The covalent linkage renders poorly immunogenic sugars potent 
antigens capable of evoking a T-cell memory response5-6. Thereby, glycoconjugation represents the key to 
render vaccination with carbohydrates efficacious in children, ensuring memory response and boost the 
response to the vaccine
.
 
The immunogenicity of carbohydrate-based vaccines is influenced by a series of interconnected variables, 
including the saccharide length, the saccharide:protein ratio in the purified conjugate, the conjugation 
strategy and the nature of the spacer. The molecular size of the carbohydrate antigen is a major concern in 
designing optimal glycoconjugates7-9. Large polysaccharides and their conjugates may have the undesirable 
property of insolubility. Size-unconstrained antigens may yield heterogeneous conjugates with the potential 
for immunogenic inconsistency10-11. Glycoconjugates constituted from size-specific antigens are thus 
particularly attractive. Although bacterial polysaccharides are usually made up of hundreds to thousands of 
 
 
repeating oligosaccharides, their antigenic structural determinants consist not of the entire polymer but 
rather of specific oligosaccharide fragments12-13. One hypothesis is that oligosaccharides containing 
complete antigenic epitopes are optimal in vaccines; however, the exploration of vaccines containing 
antigenic oligosaccharides or shorter-length polysaccharides derived from bacterial capsular polysaccharides 
has been hindered until recently by technical difficulties in chemical preparation of oligosaccharides14-15. 
There is now ample evidence that short defined carbohydrates varying from two sugar residues, as in the 
case of β-mannans from  Candida albicans16, up to the tetrasaccharide repeating unit of S. pneumoniae type 
1417 or even to an pentasaccharide in the case of Shighella serotype 2a can elicit robust production of 
functional antibodies18. 
Gram-positive Streptococcus agalactiae or Group B Streptococcus (GBS) is a leading cause of invasive 
infections in pregnant women, newborns, and elderly people19. Most GBS strains possess a capsular 
polysaccharide (PS) on their surface which is a major virulence factor. Ten different PS serotypes have been 
characterized, five of which are responsible for the vast majority of the disease in North America and 
Europe20. GBS infection can be contracted by neonates from the maternal genital tract and can result in 
prematurity or newborn bacteremia, pneumonia, and/or meningitis. Therefore, vaccination of pregnant 
women represents the best strategy for prevention of GBS infection in newborns21-22. Early in the 1930s, 
Lancefield et al. demonstrated that polyclonal antibodies from rabbit sera, able to recognize PS epitopes, 
conferred protection against GBS infection in animal models23-25. During the past two decades, plain GBS 
polysaccharides have been extensively studied as vaccines in preclinical and clinical studies26-27. However, 
the first human trials conducted in the 1980s showed that the purified native PS from serotype III was not 
sufficient to induce a robust IgG response in adults28. When the full length polysaccharide was conjugated to 
to TT or CRM197, strong long-term protection has been elicited in mice29-32. A pentavalent GBS 
polysaccharide-protein conjugate vaccine, composed of capsular epitopes from serotypes Ia, Ib, II, III and V, 
is under development. 
In order to study the effect of the saccharide length, a variety of experimental GBS type III PSIII-protein 
conjugate vaccines have been designed over the years, and their immunogenicity has been tested in 
animals33-34. Generating GBS oligosaccharides is challenging because of the acid-labile, antigenically 
critical sialic acid residues present at the termini of the side chains of all GBS PS serotypes. Enzymatic 
digestion of the type III PS with endo-β-galactosidase allowed the production of oligosaccharides with an 
average weight of 14.5 kDa covalently linked to tetanus toxoid (TT) which proved to be immunogenic in 
animals33.  
In a follow-up study, oligosaccharide with two fold smaller (7 kDa) or larger (27 kDa) size than the 
previously reported control (14.5 kDa) were examined. The conjugated medium size polymer gave the 
optimal immunogenic response (19). Large heterogeneous populations of diverse length fragments, varying 
as average weight from 11 to 100 kDa, produced according to a method developed by Laferriere and 
coworkers based on sequential N-deacetylation and nitrous acid deamination35-36, were shown by Michon 
 
 
and coworkers to induce comparable immune responses in mice in terms of anti-polysaccharide IgG levels 
and OPA titers37. 
To explain this peculiar immunological behavior of GBS PSIII, a number of structural studies were 
undertaken. PSIII was demonstrated to occasionally form extended helices with sialylated side chains 
arrayed on the exterior surface, interspersed within a major random coil structure38. According to the 
proposed model, the NeuNAc residue would not be immunodominant for PSIII antigenicity but rather be 
capital for the stabilization of the helical conformation by means of its negative charge and interactions with 
the PS backbone residues39. 
When the effect of different length oligosaccharides was taken in consideration by studying the inhibition of 
a monoclonal specific binding to PSIII, it was observed antibody recognition slightly increase when 2 and 3 
RUs were used as competitors, to be maximized at 4–5 RUs remaining constant up to 7 RUs, and to finally 
become much higher at 20 RUs. Since KD measured by SPR for 1:1 binding with the Fab remained virtually 
constant from 2 to 7 RUs it was concluded that epitope optimization was occurring from 2 to 7 RUs, while 
beyond 20 RUs this phenomenon would overlap with the multivalent exposition of stabilized epitopes40.  
Despite it was established that 2 RUs (decasaccharide) were required for suboptimal binding to homologous 
antibodies41, the antisera induced by its TT conjugate have been reported to fail at providing significant 
killing of GBSIII. The antisera raised by 3RU-TT were better but only those conjugates from 4RU-TT gave 
a comparable killing of GBSIII to antisera raised by native GBSIII-TT. The requirement of at least 4RU to 
effectively raise good protective antibodies is in agreement to the observation that an optimized 
conformational epitope forms at 4RU as indicated by binding and inhibition experiments42. 
Intrigued by these unique properties and considering the clinical relevance of GBS PSIII we recently used a 
structural glycobiolgy approach to map the polysaccharide portion binding to a protective monoclonal rabbit 
IgG. Notably we found that the epitope consists of 5 disjoined sugar residues comprised in one repeating 
unit and the GlcNAc moiety of a consecutive one. This observation contrasted the idea that the epitope 
might be exceptionally large, and convinced us to in depth explore which factors influence the 
immunogenicity of a glycoconjugate vaccine based on the minimal epitope. Here we disclose how the level 
of sugar incorporation of this defined PSIII portion onto the protein or its exposition along longer fragments 
can be tuned to achieve optimization of an anti GBSIII vaccine. 
 
 
 
 
6.2. Results 
6.2.1. Influence of the size of the oligosaccharide chains on the immunogenicity of glycoconjugates 
In order to determine whether the DP2 was not only the epitope recognized by PSIII specific antibodies (see 
Chapter 5) but also the minimal structure required to induce an immune response, oligosaccharides of 
different lengths were evaluated for their immunogenicity. For this purpose, GBSIII fragments have been 
conjugated to CRM197 (see Chapter 3 and 4 and Table 6.1). 
 
Table 6.1. Biochemical characteristics of GBS type III conjugate vaccines. 
 
 
Name 
Protein 
concentration 
(µg/mL) 
Sacch. 
Concentration 
(µg/mL) 
Average n° of saccharide 
chains per protein 
1 CRM-DP1 linear 1428 75 3.1 
2 CRM-DP1 Y-shape 1518 700 26.9 
3 CRM-DP1 branched 1268 64 3.0 
4 CRM-DP1 branched 1035 409 23.0 
5 CRM-DP2 1122 140 3.5 
6 CRM-DP2 535 160 9.0 
7 CRM-DP3 383 44 2.0 
8 CRM-DP3 484 130 4.5 
9 CRM-DP5 639 159 3.0 
10 CRM-DP5 349 161 5.5 
11 CRM-DP6,5 456 79 1.5 
12 CRM-DP6,5 289 110 3.5 
13 CRM-DP11 531 235 2.3 
 
 
 In a first set of experiments, oligosaccharide conjugates presenting comparable saccharide (mol) : protein 
(mol) ratio of 3-4 (n°1, 3, 5, 8, 9, 12, 13 in Table 6.1) were used, to rule out the effect of the glycosylation 
degree in the immunogenicity comparison. The glycoconjugates were tested in mice for their capability of 
eliciting specific anti-PSIII antibodies mediating opsonophagocytic killing (OPKA) of strains expressing 
type III PS.  
A total of 16 BALB/c female mice splitted in two identical immunization experiments received three 
intraperitoneal injections of the prepared conjugates at a saccharide dose of 0.5µg.   
The animals received booster doses of the same vaccines 3 and 5 weeks after the first immunization. All the 
glycoconjugates were formulated with Alum hydroxide and adjuvant alone was used as negative control. A 
group of mice received PS-III conjugated to CRM for comparison.  
Figure 6.1 reports the ELISA Geometric Mean Titer of IgGs raised in each group of mice after I, II, or III 
vaccine doses. 
 
 
Figure 6.1. Effect of oligosaccharide size on immunogenicity of GBS type III CRM conjugates in mice. 
IgG titers were obtained from ELISA analysis of sera from mice immunized with 1, 2 and 3 vaccine doses of 
GBSIII conjugates. 
 
 
No antibody response was detected after the first immunization, whereas all the CRM-conjugates of the 
oligomers with DP3 or higher were immunogenic after 1 and 2 booster doses. At this stage, no anti-PSIII 
antibodies were elicited by synthetic DP1s and DP2. Interestingly, DP3, DP5 and DP6.5 induced 
significantly higher level of antibodies with respect to the CRM-PSIII vaccine (p value from Mann-Whytney 
test lower than 0.001). 
Antibody functional activity was tested by an in vitro OPK assay using pooled sera from animals receiving 3 
vaccine doses. OPKA is a well-established assay that mimics the in vivo process of GBS killing subsequent 
to bacterial opsonization by effector cells in the presence of complement and specific antibodies43. In this 
assay, sera are tested at different serial dilutions and the reported OPKA titers are expressed as the 
reciprocal of the serum dilution leading to 50% bacterial killing. OPKA titers have been shown to correlate 
with mouse protection levels in a passive immunization/GBS challenge models44. 
 As shown in Figure 6.2, all conjugates with saccharide moiety of DP3 or longer elicited functional anti type 
III antibodies, and the functional activity achieved with DP3, DP5 and DP6.5 was higher than the PSIII 
conjugate. Differently from previous studies reported in literature45, this study clearly shows that fragments 
shorter than avDP4-5, which do not contain a length dependent helical structure, can be effective in eliciting 
a robust immune response in terms of antibody concentration and functional activity. 
 
 
 
Figure 6.2. Effect of oligosaccharide size on functional activity of antibodies elicited by GBS type III 
CRM conjugates in mice. OPK titers were obtained from analysis of pool of sera from mice immunized 
with 3 injections of GBSIII conjugates. 
 
6.2.2. Influence of the saccharide:protein ratio on the immunogenicity of glycoconjugates 
Since the conjugate with DP2 did not elicit an anti PSIII response, it has been evaluated whether other 
parameters would affect the immunogenicity of short oligosaccharides. Hence, an ad hoc immunization 
protocol to investigate the effects of the saccharide:protein ratio on the PS immunogenicity was designed. 8 
BALB/c mice /group were immunized with different conjugates of PS fragments showing same length but 
different glycosylation degree. Branched DP1, DP2, DP3, DP5 and DP6.5 CRM-conjugates were tested. 
Two glycosylation degrees were compared for each fragment, and conjugated native PSIII was used as 
control. 
 
 
 
 
Figure 6.3. Effect of saccharide:protein ratio size on (A) immunogenicity and (B) functional activity of 
antibodies elicited by GBS type III CRM conjugates in mice. ELISA and OPK titers were obtained from 
analysis of sera from mice immunized 3 doses of GBSIII conjugates. 
 
ELISA and OPK titers for each immunization group are reported in Figure 6.3 and, also in this case, a 
similar correlation between ELISA and functional data was observed. 
As shown, CRM conjugates elicited higher antibody titers at increasing saccharide/protein ratio. In 
particular the influence of glycosylation degree was crucial for the shortest oligosaccharides. With the 
exception of the branched DP1, where the IgG titer remained very low also for the more glycosylated 
 
 
conjugate, DP2 and DP3 were remarkably influenced by this factor. In particular, CRM-DP2 oligomer 
conjugate was not immunogenic at glycosylation degree of 3.5 while it became highly immunogenic with a 
glycosylation degree of 9.0, eliciting functional antibodies comparable to the conjugated PSIII. The CRM-
DP3 oligomer conjugate with higher glycosylation degree elicited statistically higher functional IgGs 
compared to its low glycosylated counterpart and the native PS. The difference in immunogenicity between 
lower and higher saccharide/protein ratio became less evident for longer fragments, such as DP5 and DP6.5.  
This finding highlights the potential of multivalent presentation of oligosaccharides on the carrier protein to 
achieve immunogenicity levels similar or higher than larger glycans. In particular, the minimal epitope 
appears comprised in the DP2 fragment, in line with our structural studies, and optimization of 
saccharide/protein ratio in CRM-DP2 results in a conjugate vaccine as effective as CRM-PSIII (Figure 6.3). 
Moreover an optimal immunogenicity can also occur by presentation of the short defined epitope in longer 
structures. 
 
6.2.3. Influence of the saccharide dose on the immunogenicity of glycoconjugates 
Since the novel constructs with short oligosaccharides presented higher immunogenicity levels compared to 
CRM-PSIII, it has been evaluated if this result was dose dependent. To this end, two different 
glycoconjugates were compared to CRM-PSIII at different dosages: CRM-branched DP1 (glycosylation 
degree 23.0) and CRM-DP3. Eight mice per group were immunized with 3 injections at 0.17 (except 
branched DP1), 0.5 and 1.5µg dose, respectively. Sera were analyzed by ELISA for IgG titers after 2nd and 
3rd injection (Figure 6.4). 
 
 
 
 
 
Figure 6.4. Effect of saccharide dose on immunogenicity of GBS type III CRM conjugates in mice. IgG 
titers were obtained from ELISA analysis of sera from mice immunized 2 and 3 injections of different 
vaccine doses of GBSIII conjugates. 
 
For the conjugates of the fragments DP1 and DP3, IgG titers slightly increased by injecting a higher quantity 
of the antigen; the increment was not statistically significant. For CRM-PSIII, the antibody response did not 
change, varying the dosage from 0.17 to 1.5µg. Importantly, the difference in immunogenicity between DP3 
and PSIII becomes significant only at higher dosages (0.5 and 1.5µg). 
It is worth of note that the OPK titer measured for the branched DP1 was higher at the highest dose (OPK 
titer of 136 for 1.5µg vs 20 for 0.5µg). This information could be explained considering that the antigenic 
determinant recognized by functional mAbs is almost totally contained inside the branched DP1. This 
portion would lack of the glucosamine of the second repeating unit in respect to the epitope identified by X-
ray analysis, however it would be sufficient to elicit moderate levels of functional antibodies and this feature 
would appear only at higher doses. 
 
 
 
 
 
 
 
 
6.3. Discussion 
Specific features of the conjugate design that may influence immunogenicity include choice of carrier 
protein, degree of carbohydrate loading, coupling method (random site or multisite versus single-site 
coupling), and chemical treatments that may alter the native epitope. In addition, the molecular size of the 
saccharide used in such a conjugate may be an important factor in the degree to which coupling to protein 
enhances immunogenicity.  
In this study it has been attempted to define the effect of saccharide size on immunogenicity, using model 
conjugates in which other design parameters have been carefully controlled. 
The deaminative cleavage of the native GBS type III polysaccharide followed by an improved method of 
purification of the obtained fragments allowed for the simple and well-characterized preparation of single-
ended glycoconjugates, which gave sufficient uniformity to their structures to enable a legitimate 
comparison to be made. All of the GBS PS fragments were terminally linked exclusively at the reducing 
end. In fact, the methodology offers the added advantage of arming the PS fragments with a reactive 
aldehyde group readily available for subsequent coupling to proteins by reductive amination. 
To rule out the effect of other conjugation variables, conjugates were obtained with a comparable 
saccharide:protein ratio. The results clearly show that fragments with a DP>2 are immunogenic and 
antibodies elicited are functional. In particular DP3, DP5 and DP6.5 elicit a response significantly higher 
than the native polysaccharide. 
Additional investigation is required to better understand the impact of interdependent parameters on 
immunogenicity and protective efficacy. There is no established correlation between hapten loading and 
protective efficacy8.12.46. Here, it is clearly shown that it is a critical parameter. Infact, for the conjugates 
from short oligosaccharides, with the exception of DP1, if the saccharide:protein ratio increase, the CRM 
conjugates become immunogenic (as for DP2) or elicit higher functional antibody titers (as for DP3). The 
difference in immunogenicity between lower and higher saccharide/protein ratio became less evident for 
longer fragments, such as DP5 and DP6.5.  
Regarding the influence of the dose, an increased response with higher dosages was observed for conjugates 
of GBSIII fragments, whereas CRM-PSIII elicited the same quantity of specific antibodies independently 
from the quantity of saccharide injected. CRM-DP3 can be a valid improvement in terms of immunogenicity 
for an anti GBSIII vaccine but only injecting saccharide dosages over 0.5µg where the difference in IgG titer 
is significant as compared to the CRM-PSIII conjugate. 
As already demonstrated in the previous chapter, the glycan epitope defined for GBS type III is composed of 
five disjointed residues, all comprised in the DP2 fragment. Modulating the numbers of saccharide chains 
per protein in the CRM-conjugates used as a vaccine, it has been highlighted that DP2 is also the minimal 
immunogenic fragment, eliciting functional antibodies against GBS type III with a response similar to CRM-
PSIII. Merging the two different conclusions, it can be summarized that DP2 contains the entire epitope of 
GBSIII in terms of antibody recognition and immunogenicity. 
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CHAPTER 7: CONCLUSIONS 
In this study we aimed to characterize the antigenic determinant of the capsular polysaccharide from the 
clinically relevant serotype III of GBS, a pathogen for which a vaccine is under evaluation in clinical trials.  
The GBS polysaccharide III has been considered as a conformational epitope prototype, based on NMR 
simulation studies indicating the formation of one of several potential helical structures, where sialylated 
side chains are arranged on the exterior surface of the helix. However a question was not addressed: Is the 
helical conformation pivotal for binding of PSIII to antibodies?  
We undertook a structural glycobiology approach to deeply investigate the interaction of GBSIII 
oligosaccharides obtained by synthetic and depolymerization procedures, with a protective monoclonal 
antibody: a rabbit functional monoclonal IgG belonging to the major PSIII-specific sialic-acid dependent 
population was selected. 
A combination of STD NMR and X-ray crystallography was used and the information obtained by these two 
techniques was in good agreement. In summary, from the results of these experiments, the glycan epitope for 
GBS PSIII is composed of five non-consecutive residues highlighted by the trapezoidal area (Figure 5.10a), 
and it would involve an additional GlcNAc residue of the vicinal repeating unit, as demonstrated by 
exploring the branched glycan 1 (Figure 5.6) containing the additional a GlcNAc-A'' residue. It is worth of 
note that, the β-Glc-(1→6)-β-GlcNAc linkage creates a ramification in the carbohydrate structure that is 
discriminant for mAb affinity and recognition. This creates a spatially defined but discontinuous motif 
which involves sugars from the branch and the backbone of the polysaccharide, and that can be defined as a 
conformational epitope. 
This observation contrasted the idea that the epitope might be exceptionally large, and convinced us to in 
depth explore which factors influence the immunogenicity of a glycoconjugate vaccine based on the 
minimal epitope. Here we disclose how the level of sugar incorporation of this defined PSIII portion onto 
the protein or its exposition along longer fragments can be tuned to achieve optimization of an anti GBSIII 
vaccine. Infact, modulating the numbers of saccharide chains per protein in the CRM-conjugates used as a 
vaccine, it has been highlighted that DP2 is also the minimal immunogenic fragment, eliciting functional 
antibodies against GBS type III with a response similar to CRM-PSIII. 
Merging the two different conclusions, it can be summarized that DP2 contains the entire epitope of GBSIII 
in terms of antibody recognition and immunogenicity. 
